
==== Front
BMC Genomics
BMC Genomics
BMC Genomics
1471-2164
BioMed Central London

39237910
10710
10.1186/s12864-024-10710-7
Research
Novel insights into the pleiotropic health effects of growth differentiation factor 11 gained from genome-wide association studies in population biobanks
Strosahl Jessica 1
Ye Kaixiong 23
http://orcid.org/0000-0001-9976-4817
Pazdro Robert rpazdro@uga.edu

1
1 https://ror.org/00te3t702 grid.213876.9 0000 0004 1936 738X Department of Nutritional Sciences, University of Georgia, 305 Sanford Drive, Athens, GA 30602 USA
2 https://ror.org/00te3t702 grid.213876.9 0000 0004 1936 738X Department of Genetics, University of Georgia, Athens, GA 30602 USA
3 https://ror.org/00te3t702 grid.213876.9 0000 0004 1936 738X Institute of Bioinformatics, University of Georgia, Athens, GA 30602 USA
6 9 2024
6 9 2024
2024
25 8377 3 2024
14 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Growth differentiation factor 11 (GDF11) is a member of the transforming growth factor-β (TGF-β) superfamily that has gained considerable attention over the last decade for its observed ability to reverse age-related deterioration of multiple tissues, including the heart. Yet as many researchers have struggled to confirm the cardioprotective and anti-aging effects of GDF11, the topic has grown increasingly controversial, and the field has reached an impasse. We postulated that a clearer understanding of GDF11 could be gained by investigating its health effects at the population level.

Methods and results

We employed a comprehensive strategy to interrogate results from genome-wide association studies in population Biobanks. Interestingly, phenome-wide association studies (PheWAS) of GDF11 tissue-specific cis-eQTLs revealed associations with asthma, immune function, lung function, and thyroid phenotypes. Furthermore, PheWAS of GDF11 genetic variants confirmed these results, revealing similar associations with asthma, immune function, lung function, and thyroid health. To complement these findings, we mined results from transcriptome-wide association studies, which uncovered associations between predicted tissue-specific GDF11 expression and the same health effects identified from PheWAS analyses.

Conclusions

In this study, we report novel relationships between GDF11 and disease, namely asthma and hypothyroidism, in contrast to its formerly assumed role as a rejuvenating factor in basic aging and cardiovascular health. We propose that these associations are mediated through the involvement of GDF11 in inflammatory signaling pathways. Taken together, these findings provide new insights into the health effects of GDF11 at the population level and warrant future studies investigating the role of GDF11 in these specific health conditions.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12864-024-10710-7.

Keywords

Growth differentiation factor 11
PheWAS
Asthma
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Growth Differentiation Factor 11 (GDF11) is a circulating member of the transforming growth factor β (TGF-β) superfamily that has essential roles in mammalian development. Genetic knockout studies have revealed the far-reaching effects of GDF11 on the developing embryo. Most dramatically, global, constitutive deletion of the Gdf11 gene in mice caused early mortality, with Gdf11−/− mice dying within 24 h after birth [1, 2]. Those mice also exhibited anterior homeotic transformations of the axial skeleton [1, 2], an effect mediated by Smad signaling pathways [3–5]. Other studies showed that Gdf11−/− mice exhibit renal agenesis, cleft palate [6] and greater numbers of pancreatic NGN3 + islet progenitor cells [7, 8], retinal ganglion cells [9], and olfactory epithelium progenitor cells [10], resulting from the loss of negative feedback of Gdf11 on progenitor cell number. In adult mice and humans, GDF11 has been implicated in cell differentiation and tissue repair processes, including erythropoiesis [11–13], angiogenesis [14–16], bone homeostasis [17, 18] and myogenesis [19, 20]. In humans, individuals with heterozygous loss-of-function mutations in the GDF11 gene present severe craniofacial and vertebral abnormalities, in addition to other multisystemic phenotypes such as visual and hearing disorders, cardiac abnormalities, and connective tissue dysfunction [21].

Beyond its defined roles in development, research over the past several years has indicated that GDF11 may have a powerful role in rejuvenating aged tissues, leading to a surge of interest in – and controversies surrounding – this factor. In a landmark study using heterochronic parabiosis, Loffredo et al. discovered that blood from young mice reversed age-related cardiac hypertrophy, and ultimately, GDF11 was identified as the blood-borne factor behind this effect [22]. According to the study, systemic GDF11 levels decreased with age, and treating old mice with recombinant GDF11 reversed histopathological and molecular markers of cardiac hypertrophy. Similar findings were recapitulated in other tissues, including skeletal muscle [23], brain [24–26], and skin [27–29]; meanwhile, other studies in mice and humans reported conflicting findings [30–36], claiming no effect of GDF11 on cardiac structure or function [30] or even suggesting that it is a risk factor for comorbidity and frailty in older adults with cardiovascular disease [31]. These contradictions were attributed to multiple issues – most prominent among them was the inability of various antibody-based assays to distinguish between GDF11 and its homolog, myostatin (MSTN) [22, 33, 37], which share 90% amino acid sequence identity in their mature domains [38], leading to confusion around the independent cardiac impact of each protein. But addressing these issues has not fully resolved the discrepancies in the field, as more recent studies have still presented contradictory results. Several studies reported adverse effects of GDF11 on cardiovascular and overall health [39, 40], demonstrating that GDF11 can induce cardiac dysfunction and pathologic atrophy [39] and even cause severe cachexia and death at high doses [40]. Yet most studies still support a cardioprotective role for GDF11, showing that it ameliorates pathological remodeling [41, 42], mitigates ischemia–reperfusion injury [43–45], improves outcomes in myocardial infarction [46, 47], and is associated with lower risk of cardiovascular events and death [37]. Despite a greater understanding of the factors contributing to the discrepancies across GDF11 studies, the precise health effects of this circulating protein remain unresolved.

We posited that a new understanding of GDF11 and the heart could be gained by bridging the work previously done in inbred mouse strains and studies of human participants; for this purpose, we selected an outbred mouse population [48–50] and identified a suggestive peak underlying natural variation in serum GDF11 on murine chromosome 3 [51]. The peak lies in close proximity to the protein-coding gene Hes Related Family BHLH Transcription Factor with YRPW Motif 1 (Hey1), a transcriptional repressor involved in the regulation of cardiac atrioventricular canal and vasculature development through Notch-dependent signaling pathways [52–55]. Moreover, genetic mapping of serum MSTN levels revealed a significant locus on murine chromosome 3 near the protein-coding gene Forkhead Box O1 (FoxO1). Surprisingly, statistical analyses only revealed weak, inconsistent relationships between serum GDF11 and cardiac health, whereas MSTN exhibited significant negative associations with heart weight, heart weight standardized to tibial length, and left ventricular heart wall thickness [51]. These results did not support an anti-hypertrophic effect for GDF11 but instead added to the large body of evidence suggesting that GDF11 is not a major predictor of cardiovascular health. At this point, a new approach is needed to resolve the true health effects of GDF11 in adulthood and aging.

In the present study, we sought to define the unique health effects of GDF11 at the population level – by interrogating the impact of GDF11 variants on health outcomes using published GWAS results and biobank data from large cohorts, including the UK Biobank – and contrasting the results against those from MSTN. Here, we employed a comprehensive set of analyses that utilizes the deep genetic and phenotypic data housed in public databases. We began by identifying tissue-specific cis-eQTLs [56–59], taking into account the wide range of tissues with detectable GDF11 expression in humans [60, 61] and mice [62, 63]. We then leveraged data from phenome-wide association studies (PheWAS) to identify pleiotropic effects, where a single locus affects multiple distinct phenotypes [64–66]. Finally, to evaluate the connection between the tissue-specific expression of GDF11 and human disease, we explored integrative platforms housing transcriptome-wide association study (TWAS) results and functional genomics data [67–70]. Analytical processes were performed in parallel for both GDF11 and MSTN, and we report the unique connections between traits associated with GDF11 variants and its tissue-specific expression level that expand our knowledge of the health impacts of this gene.

Methods

UK Biobank is a globally accessible, large-scale longitudinal population cohort containing genetic and disease information from over 500,000 British individuals [71]. Participants ranging from 40 to 69 years of age were recruited between the years 2006 and 2010 [71]. The North West Multi-Centre Research Ethics Committee (11/NW/ 0382) approved the UK Biobank project. Informed consent was obtained from each participant prior to collection of biological and anthropometric measurements, lifestyle indicators, blood and urine biomarkers, and information from their medical records [71].

The Genotype-Tissue Expression (GTEx) project collected 15,201 RNA-sequencing samples from 54 tissues of 838 postmortem donors. Biospecimen Source Sites (BSS) were required to submit a GTEx research protocol and undergo IRB review or forwent further review on account of deceased donors not constituting as human subjects [72, 73]. However, GTEx required explicit next-of-kin or legal representative authorization for study participation, given the public availability of the data [72]. Specific training regulating how BSS obtained consent can be found at http://gtextraining.org/. Only de-identified data according to HIPPAA policy is distributed to GTEx project collaborators [72].

Single-tissue expression-quantitative trait locus analysis

We utilized the GTEx portal to identify variants that were significantly associated with GDF11 and MSTN expression levels. Specifically, we searched for cis-eQTLs of GDF11 and MSTN across tissues. The GTEx project is an open-access database with data including gene expression, QTLs, and histology images from 54 non-diseased tissue sites across nearly 1000 individuals [74, 75]. Briefly, quality control (QC) was performed as follows: RNA-seq expression outliers were excluded based on previously described methods [76], read counts for samples were normalized and log-transformed with an offset of 1, and the read count matrix was hierarchically clustered [72]. In addition, samples with < 10 million mapped reads were removed, and if replicate samples were present, the replicate with the greatest number of reads was selected [72]. The data used for the analyses described in this manuscript were obtained from the GTEx Portal on 11/08/2022.

Transcriptome-wide association study

We used TWAS results from the TWAS Hub to identify traits associated with the tissue-specific expression of GDF11 and MSTN, as well as their putative genetic regulators, HEY1 and FOXO1, respectively. TWAS leverage gene expression measurements with summary statistics from large-scale GWAS to identify significant expression-trait associations [67]. GWAS and functional data for hundreds of traits and over 100,000 expression models were integrated within TWAS Hub [67, 77]. Summary association statistics came from 30 large-scale GWAS studies, and SNPs with minor allele frequencies of less than 1% were removed [70]. RNA sequencing data originated from CommonMind Consortium (brain, n = 613) [78], GTEx (41 tissues) [60], and the Metabolic Syndrome in Men study (adipose, N = 563) [79, 80], and expression microarray data from the Young Finns Study (blood, N = 1,264) [81, 82] and the Netherlands Twins Registry (N = 1,247) [70, 76]. Associations were considered significant if they reached the tissue-specific threshold determined by Bonferroni correction at an experimental α of 0.05, as a conservative measure.

The PhenomeXcan database was used to supplement results from the TWAS hub. PhenomeXcan is a gene-based program which houses 22,255 gene associations and 4,091 traits with transcriptome regulation data from 49 tissues in GTEx v8 using an adaptation of the PrediXcan method [83–85]. Colocalization analysis was performed via fastENLOC, a novel Bayesian hierarchical colocalization method [83, 84]. We utilized the ‘PhenomeXcan_SingleTissue' function, including 4,091 traits and 49 tissues. We only included associations that met the significance threshold p < 1e-08.

Variant-centric analysis

To investigate associations between health outcomes and variants of GDF11, HEY1, MSTN, and FOXO1, we employed the Open Target Genetics, PhenoScanner, GeneATLAS, and GWAS Catalog databases. Open Target Genetics is an open-access integrative database that combines human GWAS and functional genomics data to allow researchers to conduct systematic identification and prioritization of plausible causal variants and genes [86–88]. GWAS with and without summary statistics were sourced from the NHGRI-EBI GWAS Catalog summary statistics repository (number of studies = 300; only included associations with p ≤ 5e − 8 and removed redundant associations via distance-based clustering ± 500 kb) [89]. GWAS with full summary statistics were sourced from two GWAS analyses using UK Biobank data: the SAIGE study of binary phenotypes (number of studies = 2,139) [90], and the Neale Lab study (number of studies = 1,283) [91]. Full GWAS summary statistics were only included from those studies of predominantly European ancestries due to limited reference genotypes from other populations [87, 89]. Additionally, 92 tissue- and cell-type-specific molecular QTL (molQTL) datasets were integrated from GTEx [60], eQTLGen [92], the eQTL Catalogue, and pQTLs [93], and systematic disease-molecular trait colocalization tests were performed [87]. Variants are sorted by their locus to gene (L2G) pipeline score on a scale from 0–1 based on evidence including molecular phenotype quantitative trait loci data, chromatin interaction data, in silico functional predictions, and distance from the canonical transcript start site [86, 87]. Associations from all studies were only included if p ≤ 5e − 8 [86, 87].

PhenoScanner is a database that contains over 65 billion association results, including eQTL, pQTL, methylation QTL (mQTL), and upwards of 150 million genetic variants to enable researchers to conduct “phenome-wide scans” [94–96]. Variants with minor allele frequencies < 0.5%, multiallelic variants, and large indels (⁠ ≥ 5 bases) were removed from analyses [94, 95]. Variants were positionally annotated utilizing the Variant Effect Predictor, and traits were mapped to Experimental Factor Ontology Terms [94, 95]. The significance cut-off p < 1e–5 was used for all genes, genomic regions, and phenotypes [94, 95].

GeneATLAS utilizes the UK Biobank cohort (N = 452,264) of British individuals to systematically catalog associations between 778 traits and over 30 million variants [97, 98]. The associations were computed by use of Mixed Linear Models in a large supercomputer using the DISSECT software (freely available at https://www.dissect.ed.ac.uk under GNU Lesser General Public License v3). We utilized the GeneATLAS “region PheWAS” function to extract PheWAS associations located ± 1000 kb of our genes of interest, and significance was determined at p ≤ 1e-8. Additionally, we searched the GWAS Catalog for significant associations with the genes of interest. We only included associations that met the significance threshold p ≤ 5e − 8.

Results

Tissue-specific cis-eQTLs for GDF11 are associated with asthma, immune function, lung function, and thyroid phenotypes

To comprehensively define the health effects of GDF11 variation, we started by identifying variants that (1) lie in close proximity to the GDF11 gene and (2) are associated with its expression levels in at least one tissue. We compiled a total of 110 variants located from within ± 1 Mb of the transcription start site (TSS). Those cis-eQTLs spanned the genomic region of chr12:54,899,536–56,468,936 base pairs (bp; Supplementary Table S1), and a visual depiction of all cis-eQTLs associated with GDF11 expression is shown in Fig. 1A, which highlights a tissue-specific association pattern (Fig. 1B). From there, we narrowed the list of cis-eQTLs for further examination by selecting the most significant variant for each tissue as a representative of the haplotype block. Notably, the most significant GDF11 cis-eQTL, rs117385153, was associated with GDF11 expression in thyroid tissue (p = 6.30E-07; Table 1). A visual of all genes located in the GDF11 cis-window can be found in the Supplementary file (Supplementary Fig. S1).Fig. 1 Genetic variants significantly associated with GDF11 expression as detected in the GTEx project. A GDF11 cis-eQTLs (± 1 Mb of the transcription start site) separated by tissue. Specific tissues are denoted by colors. The most significant eQTL in each tissue is denoted by a black square. B Linkage disequilibrium (LD) blocks for GDF11 cis-eQTLs from the GTEx project. The LD heatmap reports pairwise LD values (R2) of the QTL variants. The corresponding eQTL normalized effect size (NES) bar chart heatmaps are located above the LD heatmap. Row labels (to the left of each chart) denote the tissue type and number of samples. The y-axis (to the right of each chart) is the -log10(p-value). Tissue abbreviations: ARTAORT = Artery – Aorta; BRNCHA = Brain – Cerebellum; MSCLSK = Muscle – Skeletal; SKINNS = Skin – Not Sun Exposed (Suprapubic); WHLBLD = Whole Blood. TSS = transcription start site; TES = transcription end site

Table 1 Tissue-specific GDF11 cis-eQTLs are significantly associated with asthma, immune function, lung function, and hypothyroidism in PhenoScanner. The most significant cis-eQTL from each tissue identified in the GTEx project is listed in the table. Trait associations were identified in PhenoScanner. A p-value less than 1e-5 was considered statistically significant

Cis-eQTL	eQTL p-value	cis-eQTL tissue	Trait	P-value	GWAS source	Beta	N	
rs117385153	6.30E-07	Thyroid	Self-reported pulmonary fibrosis	2.76E-05	UKBB	0.0005422	337,159	
Cause of death: asthma, unspecified	6.54E-05	UKBB	0.007471	7637	
rs7297175	0.0000068	Skeletal muscle	No blood clot, bronchitis, emphysema, asthma, rhinitis, eczema or allergy diagnosed by doctor	8.03E-19	UKBB	0.01017	336,782	
Eosinophil percentage of white cells	6.52E-14	PMID: 27863252	-0.02689	173,480	
Eosinophil count	5.02E-13	PMID: 27863252	-0.02593	173,480	
Self-reported asthma	6.16E-13	UKBB	-0.0056633	337,159	
Asthma	1.91E-12	UKBB	-0.00553	336,782	
Sum eosinophil basophil counts	5.70E-12	PMID: 27863252	-0.02474	173,480	
Eosinophil percentage of granulocytes	1.93E-11	PMID: 27863252	-0.02417	173,480	
Neutrophil percentage of granulocytes	1.30E-10	PMID: 27863252	0.02315	173,480	
Forced expiratory volume in 1-s, best measure	7.98E-07	UKBB	0.01138	255,492	
Doctor diagnosed asthma	6.60E-06	UKBB	-0.007408	83,529	
Self-reported hypothyroidism or myxoedema	1.17E-10	UKBB	-0.003373	337,159	
rs3138140	0.000015	Cerebellum	NA	NA	NA	NA	NA	
rs879920435	0.000015	Testis	NA	NA	NA	NA	NA	
rs59980219	0.000036	Aorta	NA	NA	NA	NA	NA	
rs7312770	0.000039	Unexposed suprapubic skin	No blood clot, bronchitis, emphysema, asthma, rhinitis, eczema or allergy diagnosed by doctor	3.85E-15	UKBB	-0.009001	336,782	
Self-reported asthma	2.38E-12	UKBB	0.005501	337,159	
Asthma	8.07E-12	UKBB	0.005355	336,782	
Eosinophil percentage of white cells	8.26E-11	PMID: 27863252	0.02326	173,480	
Eosinophil count	1.23E-10	PMID: 27863252	0.02307	173,480	
Sum eosinophil basophil counts	2.72E-10	PMID: 27863252	0.02265	173,480	
Eosinophil percentage of granulocytes	1.51E-08	PMID: 27863252	0.02036	173,480	
Forced expiratory volume in 1-s, best measure	1.52E-08	UKBB	-0.01301	255,492	
Neutrophil percentage of granulocytes	1.87E-08	PMID: 27863252	-0.02023	173,480	
Doctor diagnosed asthma	2.35E-06	UKBB	-0.01172	317,756	
Forced expiratory volume in 1-s	2.48E-06	UKBB	-0.009861	307,638	
Self-reported hypothyroidism or myxoedema	7.93E-09	UKBB	0.003012	337,159	
Hypothyroidism	8.00E-08	PMID: 27182965	NA	NA	
rs76779798	0.000041	Whole blood	NA	NA	NA	NA	NA	

Next, we aimed to identify the health effects of the most significant GDF11 cis-eQTL in each tissue. We began by performing a PheWAS in PhenoScanner for rs117385153, the most significant variant in thyroid tissue, and the results pointed to associations with “self-reported pulmonary fibrosis” (p = 2.76E-05) and “cause of death: asthma, unspecified” (p = 6.54E-05). Then, we performed a PheWAS for the cis-eQTLs with the highest statistical significance from other tissues. The most significant cis-eQTL in skeletal muscle tissue was rs7297175 (p = 6.8E-6), and PheWAS results for this SNP revealed associations with 11 traits related to asthma, immune function, lung function, and thyroid health (Table 1). We identified rs7312770 as the most significant cis-eQTL in unexposed suprapubic skin (p = 3.9E-5), and PheWAS analysis of this SNP indicated associations with 13 traits related to asthma, immune function, lung function, and thyroid health (Table 1). More information on sample data and procedures in unexposed suprapubic skin can be found in Supplementary Table S2. Both rs7297175 and rs7312770 exhibited the most significant association with the entry “no blood clot, bronchitis, emphysema, asthma, rhinitis, eczema or allergy diagnosed by a doctor." Lastly, the most significant cis-eQTLs in the cerebellum, testis, aorta, and whole blood were rs3138140 (p = 1.5E-5), rs879920435 (p = 1.5E-5), rs59980219 (p = 3.6E-5), and rs76779798 (p = 4.1E-5), respectively. PheWAS of these cis-eQTLs did not return any significant associations in PhenoScanner.

To contrast the health impacts of GDF11 against those of its homolog, MSTN, we searched for all MSTN cis-eQTLs in the GTEx portal and identified 771 significant variants (Supplementary Table S3). A visual depiction of all variants associated with MSTN expression can be found in Supplementary Fig. S2A. We observed a similar tissue-specific association pattern among MSTN cis-eQTLs as we previously did for those associated with GDF11 (Supplementary Fig. S2B). In contrast to GDF11, PheWAS of the most significant MSTN cis-eQTL in each tissue did not reveal consistent associations with any particular health conditions (Supplementary Table S4). As a result, we were unable to find any overlap between GDF11 and MSTN cis-eQTL PheWAS data.

Importantly, we included a positive control in the form of a benchmark gene to evaluate the reliability of our inquiry. We used a SNP (rs174546), whose PheWAS results have been previously reported [99]. We confirmed that our PheWAS of this SNP reproduced all the previously reported associations (Supplementary Table S5).

GDF11 variants demonstrate links to asthma, immune function, lung function, and thyroid health

The Open Targets Genetics Portal integrates GWAS and functional genomics data to allow for variant-centric analysis across thousands of traits. Variants were assigned to genes based on predicted functional effects, distance from the transcript start site, molecular phenotype quantitative trait loci experiments, and chromatin interaction experiments [86, 87]. To further analyze the health effects of GDF11 variants, we employed the Open Targets Genetics Portal and identified 297 associations with GDF11 variants (Supplementary Table S6). We sorted the total number of associations by disease category to identify the most prevalent health impact of GDF11 variation (Fig. 2A). Associations related to a specific disease were grouped together. For example, asthma and eosinophil counts were grouped with respiratory health, allergies, and immunity, and hypothyroidism was grouped with thyroid traits. Associations that did not easily fit a disease classification were placed in the “other” category.Fig. 2 Traits associated with variants and predicted tissue-specific expression of GDF11 and MSTN in Open Targets Genetics and the TWAS Hub. Traits were sorted by disease category to identify the most prevalent associations in each database. Disease categories are denoted by colors in the legend. Traits that did not fit a category were placed into the “other” category

Among the associations we identified with GDF11 variants, the largest portion (26.94%) were traits related to respiratory health, allergies, and immunity. The association with the highest statistical significance in this category was observed between rs705702 and “eosinophil counts” (p = 1.6E-41; Table 2), whereas the most significant association overall was between rs61134397 and “refractive error” (p = 6.0e-174). Asthma emerged as the most prevalent trait, accounting for 32.86% of all respiratory health, allergies, and immunity associations. Intriguingly, we found another GDF11 variant, rs1689510, exhibited significant associations with asthma, immune function, and lung function across multiple studies (Table 2). To further investigate this SNP, we searched for all associations with rs1689510 in the Open Targets Genetics Portal and presented those data in Fig. 3. The most statistically significant association with rs1689510 was “type 1 diabetes” (p = 5.0e-61), followed by “eosinophil percentage of white cells” (p = 8.9e-39). rs1689510 was also associated with “asthma” (p = 2.7e-23), and “hypothyroidism or myxedema” (p = 3.9e-16) (Supplementary Table S7). Table 2 GDF11 variants are associated with asthma, immune function, lung function, and hypothyroidism in Open Target Genetics. Respiratory, immune function, and lung function associations are listed together and sorted by significance. Thyroid associations are listed separately and sorted by significance. A p-value equal to or less than 5e − 8 was considered statistically significant. L2G score = “locus-to-gene” score calculated by Open Targets Genetics to weigh each association and prioritize likely candidate genes using a machine-learning model. All associations with GDF11 variants in Open Target Genetics can be found in Supplementary Table S6

Trait	Variant	N initital	P-value	GWAS Source	Reference allele	Effect allele	Beta	Odds ratio	L2G score	
Eosinophil counts	rs705702	440,275	1.60E-41	Barton AR (2021) PMID: 34226706	A	G	0.027	NA	0.022	
Eosinophil percentage of white cells	rs1689510	408,112	8.90E-39	Vuckovic D (2020) PMID: 32888494	G	C	0.029	NA	0.058	
Eosinophil counts	rs1689510	474,237	9.00E-37	Chen MH (2020) PMID: 32888493	G	C	0.027	NA	0.025	
Eosinophil counts	rs1689510	583,850	9.00E-37	Chen MH (2020) PMID: 32888493	G	C	NA	NA	0.057	
Eosinophill counts	rs1689510	408,112	6.70E-34	Vuckovic D (2020) PMID: 32888494	G	C	0.027	NA	0.048	
Eosinophill percentage	rs1689510	349,861	1.20E-31	UKB Neale v2 (2018)	G	C	0.054	NA	0.052	
Asthma	rs1689510	536,345	2.00E-31	Han Y (2020) PMID: 32296059	G	C	NA	NA	0.038	
Eosinophil counts	rs773110	440,000	4.00E-31	Kichaev G (2018) PMID: 30595370	C	G	NA	NA	0.011	
Asthma	rs7302200	341,215	8.00E-25	Ferreira MAR (2019) PMID: 30929738	G	A	NA	1.1	0.04	
Asthma (childhood onset)	rs705700	314,633	3.00E-24	Ferreira MAR (2019) PMID: 30929738	T	C	NA	NA	0.01	
Asthma	rs1689510	484,598	2.70E-23	Donertas HM (2021) PMID: 33959723	G	C	NA	1	0.05	
Asthma [conditional]	rs1689510	281,699	3.00E-20	Johansson A (2019) PMID: 31361310	G	C	NA	NA	0.036	
Lung function (FEV1/FVC)	rs1701704	371,898	6.10E-20	Barton AR (2021) PMID: 34226706	T	G	 − 0.020	NA	0.053	
Lung function (FEV1/FVC)	rs1701704	370,000	1.00E-19	Kichaev G (2018) PMID: 30595370	T	G	NA	NA	0.036	
Respiratory diseases	rs1689510	459,000	2.00E-19	Kichaev G (2018) PMID: 30595370	G	C	NA	NA	0.035	
Asthma | non-cancer illness code, self-reported	rs1689510	361,141	1.20E-18	UKB Neale v2 (2018)	G	C	NA	1.1	0.054	
Eosinophil counts	rs10876864	442,919	2.00E-18	Sakaue S (2021) PMID: 34594039	G	A	-0.015		0.011	
Asthma	rs1702877	625,448	3.00E-18	Sakaue S (2021) PMID: 34594039	C	T	0.066	NA	0.036	
Respiratory or ear nose throat disease	rs7302200	484,598	6.30E-18	Donertas HM (2021) PMID: 33959723	G	A	NA	1	0.057	
Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor	rs1689510	360,527	8.30E-18	UKB Neale v2 (2018)	G	C	NA	1.1	0.053	
Asthma (childhood onset)	rs705699	406,621	9.00E-17	Zhu Z (2019) PMID: 31669095	G	A	NA	NA	0.011	
Allergic disease (asthma, hay fever or eczema)	rs1689510	360,838	3.40E-17	Ferreira MA (2017) PMID: 29083406	G	C	NA	1.1	0.05	
Asthma	rs705700	394,283	1.00E-16	Zhu Z (2019) PMID: 31669095	T	C	NA	1.1	0.011	
Eosinophil count	rs1689510	349,856	2.20E-16	UKB Neale v2 (2018)	G	C	0.015	NA	0.05	
Atopic asthma	rs705699	417,151	4.00E-16	Zhu Z (2019) PMID: 31669095	G	A	NA	NA	0.011	
Asthma	rs1689510	408,442	6.10E-16	Valette K (2021) PMID: 34103634	G	C	NA	1.1	0.054	
Asthma	rs10876866	787,635	1.00E-15	Olafsdottir TA (2020) PMID: 31959851	G	A	NA	1.1	0.036	
Asthma (adult onset)	rs7302200	327,253	4.00E-15	Ferreira MAR (2019) PMID: 30929738	G	A	NA	NA	0.037	
Asthma	rs1701704	305,945	2.00E-14	Salinas YD (2020) PMID: 32700739	T	G	NA	1.1	0.035	
Eosinophil percentage of white cells	rs1689510	172,378	5.00E-14	Astle WJ (2016) PMID: 27863252	G	C	0.028	NA	0.054	
Asthma or allergic disease (pleiotropy)	rs10876864	116,538	1.00E-13	Zhu Z (2018) PMID: 29785011	G	A	NA	NA	0.016	
Asthma	rs1701704	4,836	2.00E-13	Hirota T (2011) PMID: 21804548	T	G	NA	1.2	0.035	
Eosinophil counts	rs7302200	172,275	3.00E-13	Astle WJ (2016) PMID: 27863252	G	A	0.027	NA	0.052	
Forced vital capacity (fvc), best measure	rs59822547	272,338	6.20E-13	UKB Neale v2 (2018)	A	G	0.027	NA	0.013	
Lymphocyte counts	rs1131017	524,923	9.80E-13	Chen MH (2020) PMID: 32888493	C	G	0.014	NA	0.015	
Sum eosinophil basophil counts	rs772920	171,771	5.30E-12	Astle WJ (2016) PMID: 27863252	C	G	0.026	NA	0.021	
Asthma (childhood onset)	rs705699	327,670	1.00E-11	Pividori M (2019) PMID: 31036433	G	A	NA	1.1	0.012	
Asthma	rs1702877	175,948	1.00E-11	Sakaue S (2021) PMID: 34594039	C	T	0.12	NA	0.031	
Eosinophil percentage of granulocytes	rs10876864	170,536	1.30E-11	Astle WJ (2016) PMID: 27863252	G	A	-0.024	NA	0.014	
Lymphocyte counts	rs1131017	408,112	3.60E-11	Vuckovic D (2020) PMID: 32888494	C	G	0.014	NA	0.02	
Neutrophil percentage of granulocytes	rs10876864	170,672	7.10E-11	Astle WJ (2016) PMID: 27863252	G	A	0.024	NA	0.015	
Forced expiratory volume in 1-s (fev1), best measure	rs1689510	272,338	3.00E-10	UKB Neale v2 (2018)	G	C	 − 0.010	NA	0.069	
Asthma	rs1702877	401,837	3.40E-10	UKB SAIGE (2018)	C	T	NA	1.1	0.052	
FEV1	rs705704	321,047	3.90E-10	Shrine N (2019) PMID: 30804560	G	A	 − 0.015	NA	0.053	
Lymphocyte counts	rs1131017	643,370	4.00E-10	Chen MH (2020) PMID: 32888493	C	G	NA	NA	0.011	
Allergic disease (asthma, hay fever or eczema)	rs11171739	102,453	4.00E-10	Zhu Z (2019) PMID: 31669095	C	T	NA	NA	0.012	
Lymophocyte percentage	12_56041720_G_C (no rsID)	349,861	4.50E-10	UKB Neale v2 (2018)	G	C	-0.11	NA	0.047	
Pediatric asthma	rs1702877	601,193	6.00E-10	Sakaue S (2021) PMID: 34594039	C	T	0.06	NA	0.032	
Asthma	rs705704	209,808	7.00E-10	Ishigaki K (2020) PMID: 32514122	G	A	NA	1.1	0.028	
Asthma (adult onset)	rs705700	426,604	1.00E-09	Zhu Z (2019) PMID: 31669095	T	C	NA	NA	0.012	
Asthma (moderate or severe)	rs7305461	30,810	1.00E-09	Shrine N (2018) PMID: 30552067	A	C	NA	0.91	0.013	
Nonatopic asthma	rs705700	450,910	2.00E-09	Zhu Z (2019) PMID: 31669095	T	C	NA	NA	0.013	
Lymphocyte percentage of white cells	rs1131017	408,112	2.70E-09	Vuckovic D (2020) PMID: 32888494	C	G	0.013	NA	0.022	
Lymphocyte counts	rs1131017	443,762	3.80E-09	Barton AR (2021) PMID: 34226706	C	G	0.012	NA	0.02	
Allergic disease (asthma, hay fever and/or eczema) (age of onset)	rs705699	117,130	4.00E-09	Ferreira MAR (2019) PMID: 30929738	G	A	-0.025	NA	0.013	
Allergic disease (asthma, hay fever and/or eczema) (multivariate analysis)	rs705699	477,968	6.00E-09	Ferreira MAR (2019) PMID: 30929738	G	A	-0.024	NA	0.013	
Forced expiratory volume in 1-s (fev1)	rs772920	329,404	6.60E-09	UKB Neale v2 (2018)	C	G	-0.0087	NA	0.022	
Lung function (FEV1/FVC)	rs61938962	321,047	7.00E-09	Shrine N (2019) PMID: 30804560	C	T	-0.015	NA	0.08	
Lung function (FEV1)	rs772920	90,715	2.00E-08	Wyss AB (2018) PMID: 30061609	C	G	NA	NA	0.017	
Hypothyroidism or myxedema	rs772920	484,598	9.50E-17	Donertas HM (2021) PMID: 33959723	C	G	NA	1	0.026	
Hypothyroidism	rs772920	459,000	7.00E-15	Kichaev G (2018) PMID: 30595370	C	G	NA	NA	0.017	
Thyroid problem (not cancer)	rs7302200	484,598	1.30E-12	Donertas HM (2021) PMID: 33959723	G	A	NA	1	0.052	
Autoimmune thyroid disease	rs2271194	755,406	2.00E-11	Saevarsdottir S (2020) PMID: 32581359	A	T	NA	NA	0.011	
Hypothyroidism, other/unspecified	rs61938963	254,846	3.10E-09	FINNGEN_R6 (2022)	C	T	NA	1.1	0.047	
Hypothyroidism	rs1131017	405,600	3.70E-08	UKB SAIGE (2018)	C	G	NA	0.93	0.017	
Hashimoto thyroiditis	rs11611029	568,833	1.00E-08	Sakaue S (2021) PMID: 34594039	C	T	-0.096	NA	0.009	
Hypothyroidism/myxoedema | non-cancer illness code, self-reported	rs1398310988	361,141	1.50E-11	UKB Neale v2 (2018)	CA	C	NA	0.92	0.015	
Hypothyroidism, strict autoimmune, 3 medication purchases required	rs705702	260,405	2.80E-10	FINNGEN_R6 (2022)	A	G	NA	1.1	0.026	
Hypothyroidism, strict autoimmune	rs61938963	235,230	3.00E-11	FINNGEN_R6 (2022)	C	T	NA	1.1	0.055	
Hypothyroidism	rs11171710	583,911	3.00E-12	Sakaue S (2021) PMID: 34594039	G	A	-0.07	NA	0.009	

Fig. 3 PheWAS results from Open Target Genetics reveal associations between the SNP rs1689510 and asthma, immune function, lung function, and hypothyroidism. The x-axis represents categories of disease traits, and the y-axis represents the -log10 (p-value) of each association. The red significance line represents p = 1e-5. Associations that met the threshold p < 1e-14 are labeled in the figure. Results are sourced from FinnGen, UK Biobank, and GWAS Catalog

To complement discoveries made with Open Targets Genetics, we employed PhenoScanner to screen for associations with GDF11 variants. We identified 34 total associations with GDF11 variants, and the most significant association overall was between rs61134397 and “cause of death: pharynx, unspecified” (p = 1.763e-21; Supplementary Table S8). The most significant respiratory association was between rs139996303 and “self-reported respiratory infection” (p = 5.46E-06; Supplementary Table S8). The investigation also revealed two GDF11 variants associated with “self-reported pulmonary fibrosis”: rs12304296 and rs7297523 (p = 8.69E-06 and p = 8.99E-06, respectively; Supplementary Table S8). Additionally, we searched for associations with GDF11 variants in GeneATLAS and identified associations with respiratory disease, asthma, and hypothyroidism, validating our previous findings (Supplementary Table S9).

Once again, we sought to contrast the health effects of GDF11 and MSTN variants, so we conducted a reciprocal analysis of MSTN in the Open Target Genetics Portal and identified 72 significant health associations (Supplementary Table S10). The results indicated that the largest number of associations with MSTN variants were red blood cell traits (43.06%), and the most significant association overall was between rs291444 and “serum levels of protein HIBCH” (p = 2.0e-258; Supplementary Table S10). The search did not reveal a robust relationship between MSTN variants and respiratory health, allergies, and immunity that was found for GDF11 (Fig. 2B). Lastly, we investigated the health effects of MSTN variants in PhenoScanner and GeneATLAS but did not identify consistent associations with a particular disease category (Supplementary Tables S11 and S12).

Predicted GDF11 expression is associated with asthma, immune function, lung function, and thyroid health

TWAS Hub is an open-access database that contains genomics data on hundreds of traits and over 100,000 expression models [67]. We identified 91 associations between tissue-specific GDF11 expression and health outcomes (Fig. 2C; Supplementary Table S13). Predictive models for the expression of GDF11 were only available for one tissue, unexposed suprapubic skin. Associations between GDF11 expression in the skin and various health conditions were compiled and sorted into disease categories; 18.18% were traits related to respiratory health, allergies, and immunity. "Blood eosinophil count" demonstrated the highest statistical significance within this category (p = 4.79E-07, Z-score = -4.9; Table 3), whereas the most significant association with GDF11 expression overall was “smoking status” (p = 1.70e-07, Z-score = 5.1). Other traits associated with GDF11 expression in this category included “respiratory disease” (p = 1.30E-06, Z-score = -4.7), “self-reported asthma” (p = 3.17E-05, Z-score = -4.0), and “lung FEV1/FVC ratio” (p = 4.81E-05, Z-score = 3.9). Furthermore, the search revealed thyroid traits associated with GDF11 expression, such as “self-reported hypothyroidism” (p = 8.54E-06, Z-score = -4.3) and “hypothyroidism/myxodema” (p = 2.07E-05, Z-score = -4.1). All associations remained significant after a tissue-specific Bonferroni correction at an experiment-wide α of 0.05 was applied. In tandem, we mined MSTN TWAS results in the TWAS hub and identified 50 significant associations. Predictive models for MSTN expression were only available for one tissue, hypothalamus. The most significant association with MSTN expression in the hypothalamus was “diastolic blood pressure, automated reading” (p = 2.60e-12, Z-score = -6.9; Supplementary Table S14), and the disease category most frequently associated with MSTN expression was cardiovascular health (20.00%; Fig. 2D). Table 3 Predicted tissue-specific GDF11 expression is associated with asthma, immune function, lung function, and thyroid traits in the TWAS Hub. Associations were identified in suprapubic unexposed skin. All associations remained significant after a tissue-specific Bonferroni correction at an experiment-wide α of 0.05 was applied. All associations with predicted tissue-specific GDF11 expression in the TWAS Hub can be found in Supplementary Table S13

Tissue	Trait	P-value	Z-score	
Suprapubic unexposed skin	Blood eosinophil count	4.79E-07	-4.9	
Respiratory disease	1.30E-06	-4.7	
Hypothyroidism (self-reported)	8.54E-06	-4.3	
Hypothyroidism/ myxodema	2.07E-05	-4.1	
Asthma (self-reported)	3.17E-05	-4	
Lung FEV1/FVC ratio	4.81E-05	3.9	
Asthma	7.23E-05	-3.8	
Lung FVC	4.66E-03	2.6	

HEY1, a candidate genetic regulator of GDF11 expression, is associated with respiratory, immune function, and thyroid health

In the next step of evaluating the respective effects of GDF11 and MSTN, we contrasted their putative genetic regulators, HEY1 and FOXO1, respectively, which we identified previously. We utilized the GTEx dataset (Supplementary Fig. S3) to contrast GDF11 and HEY1 expression across many tissues. GDF11 appeared to exhibit a similar expression pattern as HEY1 across tissues. These results indicated low MSTN expression levels across tissues relative to other genes in the query, and MSTN and FOXO1 did not appear to follow similar expression profiles across tissues. Moreover, bulk tissue expression data from the GTEx project revealed distinct expression profiles between GDF11 and MSTN. These expression data indicated the highest level of GDF11 expression in various areas of the brain, including the cervical spinal cord, cerebellum, hypothalamus, amygdala, and spleen (Fig. 4). GDF11’s expression profile provided further evidence to support the health associations we uncovered; GDF11 showed high levels of expression in the lungs and thyroid, with median bulk tissue expression levels of approximately 7 and 8 TPM, respectively. In contrast, MSTN exhibited the highest expression in cultured fibroblasts and skeletal muscle but had relatively low levels of expression across tissues compared to GDF11 (Supplementary Fig. S4).Fig. 4 Bulk tissue gene expression for GDF11 from the GTEx dataset. The x-axis represents separate tissues, and the y-axis represents expression values. Expression values are shown in TPM (transcripts per million), calculated from a gene model with isoforms collapsed to a single gene

Lastly, we sought to define the extent to which health effects of GDF11 overlapped with those of its own potential genetic regulator, HEY1. We conducted a PheWAS analysis of HEY1 in GeneATLAS and identified a total of 27 health associations (Supplementary Table S15). Interestingly, PheWAS results revealed associations between HEY1 variants and respiratory and immune function traits (Table 4). The association with the highest statistical significance was between rs3888020 and “lymphocyte count” (p = 2.43E-18). Two other HEY1 variants, rs4739738 and rs13263709, were associated with “asthma” (p = 6.40E-15 and p = 5.06E-12, respectively). Furthermore, we searched PhenomeXcan for TWAS results and identified associations between tissue-specific HEY1 expression and respiratory and thyroid phenotypes (Table 5). The strongest respiratory-related association with HEY1 expression across all tissues with available data was “diagnoses—main ICD10: J39 Other diseases of upper respiratory tract” (p = 2.35E-4) and was identified in the minor salivary gland tissue. Thyroid traits associated with HEY1 expression in PhenomeXcan included “non-cancer illness code, self-reported: thyroid problem (not cancer)” identified in the minor salivary gland (p = 9.06E-3) and hypothalamus (p = 1.53E-2), and “hypothyroidism (congenital or acquired)” identified in the testis (p = 9.89E-3). All associations with tissue-specific HEY1 expression identified in PhenomeXcan can be found in Supplementary Table S16. Using the GWAS Catalog, we uncovered associations between HEY1 variants and various health outcomes, including educational attainment and colorectal cancer survival, though none of which overlapped with respiratory, lung function, immune function, or thyroid traits (Supplementary Table S17). Of note, we investigated the other HEY family genes and the results were consistent with those for HEY1 (Supplementary Table S18). Table 4 HEY1 variants are associated with respiratory and immune function traits in GeneATLAS. Associations were identified using the “Region PheWAS” function in GeneATLAS. A p-value less than 0.05 was considered statistically significant. All associations with HEY1 variants in GeneATLAS can be found in Supplementary Table S15

Trait	Variant	P-value	
Lymphocyte count	rs3888020	2.43E-18	
Lymphocyte percentage	rs3888020	1.87E-17	
Asthma	rs4739738	6.40E-15	
Neutrophil percentage	rs3888020	9.12E-15	
Eosinophil percentage	rs13263709	2.73E-12	
J45 Asthma	rs13263709	5.06E-12	
Eosinophil count	rs13263709	5.47E-12	
J40-J47 Chronic lower respiratory diseases	rs4739738	6.63E-11	
J40-J47 Chronic lower respiratory diseases	rs1702877	6.63E-11	
White blood cell (leukocyte) count	rs12677936	7.92E-11	
Monocyte percentage	rs3888020	2.08E-10	

Table 5 Predicted tissue-specific HEY1 expression is associated with respiratory and thyroid traits in PhenomeXcan. The respective tissue where each association was detected is listed in the table. A p-value less than 0.05 was considered statistically significant. All associations with predicted tissue-specific HEY1 expression can be found in Supplementary Table S16

Trait	Tissue	P-value	Z-score	
Diagnoses—main ICD10: J39 Other diseases of upper respiratory tract	Minor salivary gland	2.35E-4	-3.68	
Diagnoses—main ICD10: J39 Other diseases of upper respiratory tract	Pituitary; Brain_Nucleus_accumbens_basal_ganglia; Brain_Caudate_basal_ganglia; Brain_Putamen_basal_ganglia	9.08E-4	3.32	
Underlying (primary) cause of death: ICD10: C34.9 Bronchus or lung, unspecified	Skeletal muscle	3.43E-3	2.93	
Recent medication for asthma	Skeletal muscle	5.79E-3	2.76	
Non-cancer illness code, self-reported: thyroid problem (not cancer)	Minor salivary gland	9.06E-3	-2.61	
Hypothyroidism (congenital or acquired)	Testis	9.89E-3	2.58	
Non-cancer illness code, self-reported: thyroid problem (not cancer)	Hypothalamus	1.53E-2	-2.42	

Finally, to be as comprehensive as possible, we searched for overlap between MSTN and its potential genetic regulator, FOXO1, and identified shared associations between these genes in several databases (Supplementary Tables S19-S22). A flow chart depicting the study design and overarching results for each gene included in this study can be found in Fig. 5.Fig. 5 Overarching study design and results flow chart for GDF11, MSTN, HEY1, and FOXO1. Each step of the study design and corresponding databases are depicted to the left of the vertical black line. Overarching results for each gene identified from each step are depicted to the right of the vertical black line

Discussion

In the present study, we sought to define the unique health effects of GDF11 at the population level, versus that of its homolog MSTN, using repositories of published GWAS results in population biobanks. Prior studies had demonstrated roles for GDF11 in rejuvenating the aged heart [22, 100], brain [24–26], and skeletal muscle [23], so we predicted that GDF11 variants would be associated with cardiovascular, cognitive, and muscular diseases and phenotypes. Yet our results revealed consistent relationships between GDF11 and respiratory, immune function, and thyroid health instead. PheWAS of GDF11 cis-eQTLs revealed associations with asthma, lung function, immune function, and thyroid health, and PheWAS of broader GDF11 variants and TWAS of its predicted tissue-specific expression confirmed those findings. Through our comprehensive approach, we documented novel associations with GDF11, expanding our knowledge of the pleiotropic health effects of this gene.

Our analysis revealed that GDF11 variants and its predicted tissue-specific expression levels were consistently associated with asthma across multiple databases. Asthma is a chronic inflammatory lung disease characterized by airflow obstruction in which airway smooth muscle constricts due to a variety of triggers, such as allergens, tobacco smoke, air pollution, and infections [101, 102]. Asthma affects over 300 million individuals worldwide and claimed over 455,000 deaths in 2019, according to the Global Burden of Disease study [103, 104]. Asthma, like many other chronic conditions, is polygenic – driven by complex interactions among many genes and variants. Human GWAS consistently implicate the 17q21 locus with asthma, and variants of four genes within this locus have been linked to the development of the disease [105]. Mutations in these genes, including ORMDL3, GSDMB, ZPBP2, and IKZF3, result in reduced protein folding in the endoplasmic reticulum leading to an overall pro-inflammatory effect in asthma patients [106]. However, as with other complex genetic diseases, much of its heritability remains undefined [106]. In addition to the presence of asthma, in our study, GDF11 variants and transcript levels were also associated with blood eosinophil counts. These data are supportive of a potential relationship between GDF11 and asthma due to the major role eosinophils play in asthma pathogenesis. In T2 high asthma, distinguished by eosinophilic inflammation in the airways [107], eosinophils are recruited to the inflammatory site and release inflammatory mediators such as cytokines and chemokines [108]. Furthermore, sputum and blood eosinophil counts have been used as clinical biomarkers for disease exacerbation [109–111]. In this study, we identified high GDF11 expression levels in the spleen, consistent with findings from past studies [112, 113]. The spleen has a broad range of immunological functions and contains several types of resident immune cells, including T and B cells, dendritic cells, and macrophages [114–116]. These results suggest GDF11 may influence the development or progression of asthma through its relationship with the immune system. Future research will expand our understanding of asthma genetics, including the relationship between GDF11, asthma, and the immune system.

Furthermore, our results pointed to a relationship between GDF11 and thyroid phenotypes, particularly hypothyroidism. Hypothyroidism is a chronic disease characterized by a deficiency in thyroxine (T4) and triiodothyronine (T3) [117], with an estimated worldwide prevalence of 5% [118]. While environmental iodine deficiency is the most common cause of hypothyroidism globally, autoimmune thyroiditis (Hashimoto’s disease) is the leading cause of primary hypothyroidism in regions of iodine sufficiency [119]. Hypothyroidism results from pathological processes within the thyroid gland (primary hypothyroidism) but can also develop from hypothalamus or pituitary disorders (central hypothyroidism) or disorders of the peripheries [119, 120]. The genetic basis of hypothyroidism has yet to be well-defined [119], although GWAS have identified common loci associated with thyroid hormone regulation [121–123]. Interestingly, a recent study by Añón-Hidalgo et al. identified a positive association between GDF11 and TSH levels in humans [124], supporting the relationship we found between GDF11 and hypothyroidism. Importantly, the top cis-eQTL of GDF11, rs117385153, was identified in the thyroid tissue, and bulk tissue expression from the GTEx dataset supports this finding, revealing moderate GDF11 expression levels in the thyroid tissue. Collectively, these data highlight a consistency between the genetic regulation of GDF11 and its associations with hypothyroidism, supporting the potential role of GDF11 in the development or progression of thyroid disease.

We propose that the associations identified within this study, linking GDF11 variants and transcript levels to respiratory and thyroid phenotypes—specifically asthma and hypothyroidism—are mediated through the involvement of GDF11 in inflammatory signaling pathways. The relationship between GDF11 and inflammation has been reported in prior studies, particularly by its attenuation of inflammatory factor expression by impeding nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and JNK signaling pathways through TGF-β/Smad2/3 activation [27, 124–128]. Through its anti-inflammatory actions, GDF11 has been shown to be beneficial by relieving acute lung injury [127], the development of inflammatory arthritis [125], endothelial injury and atherosclerotic lesion formation [126], and aging of the skin [27]. Moreover, prior studies in humans with chronic obstructive pulmonary disease (COPD) report decreases in circulating GDF11 levels [128, 129] and reduced GDF11 expression in the serum and cells of these patients [130]. Asthma and hypothyroidism are complex, chronic conditions whose pathogeneses and progression are largely dictated by inflammation [131–133]. Both conditions are often diagnosed in individuals with autoimmune disorders, such as Type 1 diabetes [117, 134]. Asthma and thyroid diseases have been correlated with each other in several studies [135–146], but the research is mostly limited to association data. These reports include case studies that identify patients afflicted by both diseases [143, 142], epidemiological evidence from the Oxford Record Linkage Study (ORLS) supporting a possible association between the two conditions [137], and a population-based cohort study suggesting maternal hypothyroidism may increase the risk of childhood asthma [144]. Several studies report associations between hypothyroidism and milder asthma symptoms [140, 145, 146], potentially due to reduced thyroid hormone levels which cause decreased oxygen consumption [147]. We posit that GDF11 influences respiratory and thyroid health, particularly asthma and hypothyroidism, through its anti-inflammatory effects. To our knowledge, no group has reported a connection between GDF11, asthma, and hypothyroidism simultaneously, warranting future research on the potential role of GDF11 in the pathogenesis of these conditions.

One SNP identified in Open Target Genetics, rs1689510, was found to be associated with asthma, immune function, lung function, and thyroid traits across multiple studies. PheWAS results from FinnGen, UK Biobank, and GWAS Catalog for this SNP indicate significant associations with type 1 diabetes, asthma, immune function, and hypothyroidism. These findings highlight a major advantage of PheWAS – the ability to identify a single locus that affects multiple distinct phenotypes – and provide pleiotropic variants to inform the next steps in this research. For instance, mechanistic investigations are now needed to test and validate rs1689510 as a key player in asthma pathogenesis. rs1689510 is located 259,862 bp away from GDF11’s canonical transcription start site (TSS), and upon further investigation, we identified this variant as a cis-eQTL of GDF11 in the eQTL Gen database [92]. The nearest gene to rs1689510 is IKAROS family zinc finger 4 (IKZF4; 4,675 bp to canonical TSS), which encodes a protein that binds to the 5'GGGAATRCC-3' Ikaros-binding sequence and serves as a transcriptional repressor [148]. Results from the GTEx portal indicate that rs1689510 is a cis-eQTL of IKZF4 in adipose tissue (p = 6.6E-08), lymphocytes (p = 1.2E-06), and unexposed suprapubic skin (p = 3.7E-05). Intriguingly, IKZF4 has been shown to be necessary for the inhibitory role of T-regulatory cells [149, 150], suggesting rs1689510 may regulate the predicted expression levels of several genes involved in immune function, including IKZF4 and GDF11. Overall, these results encourage future studies on the role rs1689510 plays in the immune system and disease progression and development, particularly asthma.

In our prior rodent work, we provided evidence of members of the hairy and enhancer of split-related (HESR) family of basic helix-loop-helix (bHLH) transcriptional repressors [151], specifically Hey1, as genetic regulators of GDF11 [51]. In the present study, gene expression results from the GTEx dataset indicate similar expression patterns for GDF11 and HEY1 across tissues. These relationships remain, although less consistently, between GDF11 and other HEY family genes. These human expression data mirror those of mice, wherein Gdf11 and Hey family genes are positively correlated with each other [152]. Moreover, we noted general associations between HEY1 variants and its predicted tissue-specific expression levels with respiratory and thyroid conditions, as we did for GDF11. These results are consistent with HEY1 as a potential genetic regulator of GDF11, specifically in the context of inflammatory disease. We also investigated the homolog of GDF11, MSTN, to parse out their distinct biological roles. Results mirror MSTN’s known role in the heart [153–156], as many associations were related to cardiovascular health. However, MSTN did not share the same robust relationship with respiratory, lung function, immune function, and thyroid traits as GDF11 did. This suggests that GDF11 has a separate, distinct role in the development of inflammatory diseases that is not shared with MSTN. Future work should continue to delineate the shared and distinct functions of these homologs.

It must be noted that there are several limitations to our study. First, we applied Bonferroni correction on many transcriptome-wide associations to establish a conservative significance threshold, but not all of our variables were truly independent [157]. TWAS results were based on genetically predicted gene expression, not direct measurements of gene expression – TWAS signals rely on the predictive power of the genetic model to compute gene expression and GWAS to source variant-level trait associations. Furthermore, our stratified approach used multiple databases to gather evidence; however, these databases were not completely independent from one another. Some of the consistent observations we identified between databases were due to the same underlying GWAS results housed in several platforms. Importantly, these databases primarily include British individuals, which affords them limited ancestral diversity. It is imperative that future studies investigate these genotype–phenotype relationships in populations with greater genetic diversity. Lastly, due to incomplete linkage disequilibrium (LD) between SNPs and the availability of SNPs in the databases used in this study, we did observe trait associations for some SNPs within LD blocks, but not others. In the interest of communicating the novel relationships identified between GDF11 and health, we included all reported significant associations to be comprehensive.

In this study, we provide evidence of GDF11 in the involvement of inflammatory diseases, namely asthma and hypothyroidism. PheWAS revealed robust associations between GDF11 cis-eQTLs and asthma, immune function, lung function, and thyroid health. Associations identified from PheWAS on GDF11 variants and TWAS on predicted GDF11 tissue-specific expression confirmed our findings. Secondarily, we found similar health associations with HEY1 as we did with GDF11, supporting our previous work which identified HEY1 as a candidate genetic regulator of GDF11 in the DO mouse stock. Moreover, gene expression data strengthen our hypotheses that GDF11 is involved in respiratory and thyroid disease pathogenesis and that HEY1 regulates GDF11. Through these efforts, we report novel relationships between GDF11 and disease, suggesting GDF11 may exert its effects by acting on inflammatory pathways, in contrast to its formerly assumed role as a rejuvenating factor in basic aging. These data provide novel insights into the health impacts of GDF11 and lend further support for future mechanistic studies to illuminate the precise role of GDF11 in inflammatory disease pathogenesis.

Supplementary Information

Supplementary Material 1.

Abbreviations

DO Diversity Outbred

FoxO1 Forkhead Box O1

GDF11 Growth differentiation factor 11

Hey1 Hes Related Family BHLH Transcription Factor with YRPW Motif 1

MSTN Myostatin

PheWAS Phenome-wide association study

SNP Single nucleotide polymorphism

TWAS Transcriptome-wide association study

TGF-β Transforming growth factor-β

Acknowledgements

The authors wish to acknowledge Abigail DeBacker for her contributions to this work.

Authors’ contributions

K.Y. guided the study design; J.S. collected and analyzed the data; R.P. supervised the project. All authors participated in writing the manuscript; all authors approved the final manuscript.

Funding

This work was supported by National Institutes of Health grant GM121551 (R.P.).

Availability of data and materials

All data analyzed during this study are included in this published article and its supplementary information files. All data was downloaded from open-access databases, and details with links can be found in references [ 79, 80, 89, 92, 100, 102].

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. McPherron AC Huynh TV Lee SJ Redundancy of myostatin and growth/differentiation factor 11 function BMC Dev Biol 2009 9 24 10.1186/1471-213X-9-24 19298661
McPherron AC, Huynh TV, Lee SJ. Redundancy of myostatin and growth/differentiation factor 11 function. BMC Dev Biol. 2009;9:24.19298661 10.1186/1471-213X-9-24
2. McPherron A Lawler A Lee SJ Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11 Nat Genet 1999 22 260 264 10.1038/10320 10391213
McPherron A, Lawler A, Lee SJ. Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nat Genet. 1999;22:260–4.10391213 10.1038/10320
3. Andersson O Reissmann E Ibanez CF Growth differentiation factor 11 signals through the transforming growth factor-β receptor ALK5 to regionalize the anterior–posterior axis EMBO Rep 2006 7 8 831 837 10.1038/sj.embor.7400752 16845371
Andersson O, Reissmann E, Ibanez CF. Growth differentiation factor 11 signals through the transforming growth factor-β receptor ALK5 to regionalize the anterior–posterior axis. EMBO Rep. 2006;7(8):831–7.16845371 10.1038/sj.embor.7400752
4. Oh SP Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning Genes Dev 2002 16 21 2749 2754 10.1101/gad.1021802 12414726
Oh SP, et al. Activin type IIA and IIB receptors mediate Gdf11 signaling in axial vertebral patterning. Genes Dev. 2002;16(21):2749–54.12414726 10.1101/gad.1021802
5. Zhang Y Role of growth differentiation factor 11 in development, physiology and disease Oncotarget 2017 8 46 81604 81616 10.18632/oncotarget.20258 29113418
Zhang Y, et al. Role of growth differentiation factor 11 in development, physiology and disease. Oncotarget. 2017;8(46):81604–16.29113418 10.18632/oncotarget.20258
6. Esquela AF Lee S-J Regulation of metanephric kidney development by growth/differentiation factor 11 Dev Biol 2003 257 2 356 370 10.1016/S0012-1606(03)00100-3 12729564
Esquela AF, Lee S-J. Regulation of metanephric kidney development by growth/differentiation factor 11. Dev Biol. 2003;257(2):356–70.12729564 10.1016/S0012-1606(03)00100-3
7. Harmon EB, et al. GDF11 modulates NGN3+ islet progenitor cell number and promotes β-cell differentiation in pancreas development. Development. 2004;131(24):6163–74.
8. Dichmann DS Yassin H Serup P Analysis of pancreatic endocrine development in GDF11-deficient mice Dev Dyn 2006 235 11 3016 3025 10.1002/dvdy.20953 16964608
Dichmann DS, Yassin H, Serup P. Analysis of pancreatic endocrine development in GDF11-deficient mice. Dev Dyn. 2006;235(11):3016–25.16964608 10.1002/dvdy.20953
9. Kim J GDF11 controls the timing of progenitor cell competence in developing retina Science 2005 308 5730 1927 1930 10.1126/science.1110175 15976303
Kim J, et al. GDF11 controls the timing of progenitor cell competence in developing retina. Science. 2005;308(5730):1927–30.15976303 10.1126/science.1110175
10. Wu H-H Autoregulation of neurogenesis by GDF11 Neuron 2003 37 2 197 207 10.1016/S0896-6273(02)01172-8 12546816
Wu H-H, et al. Autoregulation of neurogenesis by GDF11. Neuron. 2003;37(2):197–207.12546816 10.1016/S0896-6273(02)01172-8
11. Rochette L Growth and differentiation factor 11 (GDF11): functions in the regulation of erythropoiesis and cardiac regeneration Pharmacol Ther 2015 156 26 33 10.1016/j.pharmthera.2015.10.006 26523637
Rochette L, et al. Growth and differentiation factor 11 (GDF11): functions in the regulation of erythropoiesis and cardiac regeneration. Pharmacol Ther. 2015;156:26–33.26523637 10.1016/j.pharmthera.2015.10.006
12. Dussiot M An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia Nat Med 2014 20 4 398 407 10.1038/nm.3468 24658077
Dussiot M, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med. 2014;20(4):398–407.24658077 10.1038/nm.3468
13. Suragani RN Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis Nat Med 2014 20 4 408 414 10.1038/nm.3512 24658078
Suragani RN, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408–14.24658078 10.1038/nm.3512
14. Liu Z Long-term intermittent fasting improves neurological function by promoting angiogenesis after cerebral ischemia via growth differentiation factor 11 signaling activation PLoS ONE 2023 18 3 e0282338 10.1371/journal.pone.0282338 36996042
Liu Z, et al. Long-term intermittent fasting improves neurological function by promoting angiogenesis after cerebral ischemia via growth differentiation factor 11 signaling activation. PLoS ONE. 2023;18(3):e0282338.36996042 10.1371/journal.pone.0282338
15. Yu X Growth Differentiation Factor 11 Promotes Abnormal Proliferation and Angiogenesis of Pulmonary Artery Endothelial Cells Hypertension 2018 71 4 729 741 10.1161/HYPERTENSIONAHA.117.10350 29463625
Yu X, et al. Growth Differentiation Factor 11 Promotes Abnormal Proliferation and Angiogenesis of Pulmonary Artery Endothelial Cells. Hypertension. 2018;71(4):729–41.29463625 10.1161/HYPERTENSIONAHA.117.10350
16. Lu L, et al. Growth Differentiation Factor 11 Promotes Neurovascular Recovery After Stroke in Mice. Front Cell Neurosci. 2018;12:205.
17. Chen Y Relationship of serum GDF11 levels with bone mineral density and bone turnover markers in postmenopausal Chinese women Bone Research 2016 4 1 1 5 10.1038/boneres.2016.12
Chen Y, et al. Relationship of serum GDF11 levels with bone mineral density and bone turnover markers in postmenopausal Chinese women. Bone Research. 2016;4(1):1–5.10.1038/boneres.2016.12
18. Zhang Y Growth differentiation factor 11 is a protective factor for osteoblastogenesis by targeting PPARgamma Gene 2015 557 2 209 214 10.1016/j.gene.2014.12.039 25534870
Zhang Y, et al. Growth differentiation factor 11 is a protective factor for osteoblastogenesis by targeting PPARgamma. Gene. 2015;557(2):209–14.25534870 10.1016/j.gene.2014.12.039
19. Jeanplong F, et al. Growth and differentiation factor-11 is developmentally regulated in skeletal muscle and inhibits myoblast differentiation. Open J Mol Integr Physiol. 2012;2:127–38.
20. Egerman MA GDF11 increases with age and inhibits skeletal muscle regeneration Cell Metab 2015 22 1 164 174 10.1016/j.cmet.2015.05.010 26001423
Egerman MA, et al. GDF11 increases with age and inhibits skeletal muscle regeneration. Cell Metab. 2015;22(1):164–74.26001423 10.1016/j.cmet.2015.05.010
21. Ravenscroft TA Heterozygous loss-of-function variants significantly expand the phenotypes associated with loss of GDF11 Genet Med 2021 23 10 1889 1900 10.1038/s41436-021-01216-8 34113007
Ravenscroft TA, et al. Heterozygous loss-of-function variants significantly expand the phenotypes associated with loss of GDF11. Genet Med. 2021;23(10):1889–900.34113007 10.1038/s41436-021-01216-8
22. Poggioli T Circulating growth differentiation factor 11/8 levels decline with age Circ Res 2016 118 1 29 37 10.1161/CIRCRESAHA.115.307521 26489925
Poggioli T, et al. Circulating growth differentiation factor 11/8 levels decline with age. Circ Res. 2016;118(1):29–37.26489925 10.1161/CIRCRESAHA.115.307521
23. Sinha M Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle Science 2014 344 6184 649 652 10.1126/science.1251152 24797481
Sinha M, et al. Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014;344(6184):649–52.24797481 10.1126/science.1251152
24. Katsimpardi L Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors Science 2014 344 6184 630 634 10.1126/science.1251141 24797482
Katsimpardi L, et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014;344(6184):630–4.24797482 10.1126/science.1251141
25. Shi Y Liu J-P Gdf11 facilitates temporal progression of neurogenesis in the developing spinal cord J Neurosci 2011 31 3 883 893 10.1523/JNEUROSCI.2394-10.2011 21248112
Shi Y, Liu J-P. Gdf11 facilitates temporal progression of neurogenesis in the developing spinal cord. J Neurosci. 2011;31(3):883–93.21248112 10.1523/JNEUROSCI.2394-10.2011
26. Vanbekbergen N Hendrickx M Leyns L Growth differentiation factor 11 is an encephalic regionalizing factor in neural differentiated mouse embryonic stem cells BMC Res Notes 2014 7 1 1 7 10.1186/1756-0500-7-766 24382056
Vanbekbergen N, Hendrickx M, Leyns L. Growth differentiation factor 11 is an encephalic regionalizing factor in neural differentiated mouse embryonic stem cells. BMC Res Notes. 2014;7(1):1–7.24382056 10.1186/1756-0500-7-766
27. Rochette L Anti-aging effects of GDF11 on skin Int J Mol Sci 2020 21 7 2598 10.3390/ijms21072598 32283613
Rochette L, et al. Anti-aging effects of GDF11 on skin. Int J Mol Sci. 2020;21(7):2598.32283613 10.3390/ijms21072598
28. Tito A The growth differentiation factor 11 is involved in skin fibroblast ageing and is induced by a preparation of peptides and sugars derived from plant cell cultures Mol Biotechnol 2019 61 3 209 220 10.1007/s12033-019-00154-w 30661170
Tito A, et al. The growth differentiation factor 11 is involved in skin fibroblast ageing and is induced by a preparation of peptides and sugars derived from plant cell cultures. Mol Biotechnol. 2019;61(3):209–20.30661170 10.1007/s12033-019-00154-w
29. Kim Y-J Conditioned media from human umbilical cord blood-derived mesenchymal stem cells stimulate rejuvenation function in human skin Biochemistry and biophysics reports 2018 16 96 102 10.1016/j.bbrep.2018.10.007 30417126
Kim Y-J, et al. Conditioned media from human umbilical cord blood-derived mesenchymal stem cells stimulate rejuvenation function in human skin. Biochemistry and biophysics reports. 2018;16:96–102.30417126 10.1016/j.bbrep.2018.10.007
30. Smith SC GDF11 does not rescue aging-related pathological hypertrophy Circ Res 2015 117 11 926 932 10.1161/CIRCRESAHA.115.307527 26383970
Smith SC, et al. GDF11 does not rescue aging-related pathological hypertrophy. Circ Res. 2015;117(11):926–32.26383970 10.1161/CIRCRESAHA.115.307527
31. Schafer MJ Quantification of GDF11 and myostatin in human aging and cardiovascular disease Cell Metab 2016 23 6 1207 1215 10.1016/j.cmet.2016.05.023 27304512
Schafer MJ, et al. Quantification of GDF11 and myostatin in human aging and cardiovascular disease. Cell Metab. 2016;23(6):1207–15.27304512 10.1016/j.cmet.2016.05.023
32. Glass DJ Elevated GDF11 is a risk factor for age-related frailty and disease in humans Cell Metab 2016 24 1 7 8 10.1016/j.cmet.2016.06.017 27411004
Glass DJ. Elevated GDF11 is a risk factor for age-related frailty and disease in humans. Cell Metab. 2016;24(1):7–8.27411004 10.1016/j.cmet.2016.06.017
33. Egerman MA Glass DJ The role of GDF11 in aging and skeletal muscle, cardiac and bone homeostasis Crit Rev Biochem Mol Biol 2019 54 2 174 183 10.1080/10409238.2019.1610722 31144559
Egerman MA, Glass DJ. The role of GDF11 in aging and skeletal muscle, cardiac and bone homeostasis. Crit Rev Biochem Mol Biol. 2019;54(2):174–83.31144559 10.1080/10409238.2019.1610722
34. Rodgers BD The Immateriality of circulating GDF11 Circ Res 2016 118 10 1472 1474 10.1161/CIRCRESAHA.116.308478 27174947
Rodgers BD. The Immateriality of circulating GDF11. Circ Res. 2016;118(10):1472–4.27174947 10.1161/CIRCRESAHA.116.308478
35. Rodgers BD Eldridge JA Reduced Circulating GDF11 Is Unlikely Responsible for Age-Dependent Changes in Mouse Heart, Muscle, and Brain Endocrinology 2015 156 11 3885 3888 10.1210/en.2015-1628 26372181
Rodgers BD, Eldridge JA. Reduced Circulating GDF11 Is Unlikely Responsible for Age-Dependent Changes in Mouse Heart, Muscle, and Brain. Endocrinology. 2015;156(11):3885–8.26372181 10.1210/en.2015-1628
36. Zhou Y GDF11 treatment attenuates the recovery of skeletal muscle function after injury in older rats AAPS J 2017 19 2 431 437 10.1208/s12248-016-0024-x 27924614
Zhou Y, et al. GDF11 treatment attenuates the recovery of skeletal muscle function after injury in older rats. AAPS J. 2017;19(2):431–7.27924614 10.1208/s12248-016-0024-x
37. Olson KA Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts Eur Heart J 2015 36 48 3426 3434 10.1093/eurheartj/ehv385 26294790
Olson KA, et al. Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts. Eur Heart J. 2015;36(48):3426–34.26294790 10.1093/eurheartj/ehv385
38. Nakashima M Akamine TTA Joyner A Expression of growth/differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis Mech Dev 1999 80 2 185 9 10.1016/S0925-4773(98)00205-6 10072786
Nakashima M, Akamine TTA, Joyner A. Expression of growth/differentiation factor 11, a new member of the BMP/TGFbeta superfamily during mouse embryogenesis. Mech Dev. 1999;80(2):185–9.10072786 10.1016/S0925-4773(98)00205-6
39. Roh, J.D., et al., Activin type II receptor signaling in cardiac aging and heart failure. Sci Transl Med, 2019. 11(482).
40. Harper SC Decreases pressure overload-induced hypertrophy, but can cause severe cachexia and premature death Circ Res 2018 123 11 1220 1231 10.1161/CIRCRESAHA.118.312955 30571461
Harper SC, et al. Decreases pressure overload-induced hypertrophy, but can cause severe cachexia and premature death. Circ Res. 2018;123(11):1220–31.30571461 10.1161/CIRCRESAHA.118.312955
41. Garrido-Moreno V GDF-11 prevents cardiomyocyte hypertrophy by maintaining the sarcoplasmic reticulum-mitochondria communication Pharmacol Res 2019 146 104273 10.1016/j.phrs.2019.104273 31096010
Garrido-Moreno V, et al. GDF-11 prevents cardiomyocyte hypertrophy by maintaining the sarcoplasmic reticulum-mitochondria communication. Pharmacol Res. 2019;146:104273.31096010 10.1016/j.phrs.2019.104273
42. Zhu HZ GDF11 Alleviates Pathological Myocardial Remodeling in Diabetic Cardiomyopathy Through SIRT1-Dependent Regulation of Oxidative Stress and Apoptosis Front Cell Dev Biol 2021 9 686848 10.3389/fcell.2021.686848 34262905
Zhu HZ, et al. GDF11 Alleviates Pathological Myocardial Remodeling in Diabetic Cardiomyopathy Through SIRT1-Dependent Regulation of Oxidative Stress and Apoptosis. Front Cell Dev Biol. 2021;9: 686848.34262905 10.3389/fcell.2021.686848
43. Su HH Exogenous GDF11 attenuates non-canonical TGF-beta signaling to protect the heart from acute myocardial ischemia-reperfusion injury Basic Res Cardiol 2019 114 3 20 10.1007/s00395-019-0728-z 30900023
Su HH, et al. Exogenous GDF11 attenuates non-canonical TGF-beta signaling to protect the heart from acute myocardial ischemia-reperfusion injury. Basic Res Cardiol. 2019;114(3):20.30900023 10.1007/s00395-019-0728-z
44. Chen L Growth differentiation factor 11 attenuates cardiac ischemia reperfusion injury via enhancing mitochondrial biogenesis and telomerase activity Cell Death Dis 2021 12 7 665 10.1038/s41419-021-03954-8 34215721
Chen L, et al. Growth differentiation factor 11 attenuates cardiac ischemia reperfusion injury via enhancing mitochondrial biogenesis and telomerase activity. Cell Death Dis. 2021;12(7):665.34215721 10.1038/s41419-021-03954-8
45. Bin Z GDF11 ameliorated myocardial ischemia reperfusion injury by antioxidant stress and up-regulating autophagy in STZ-induced type 1 diabetic rats Acta Cir Bras 2020 34 11 e201901106 10.1590/s0102-865020190110000006 31939595
Bin Z, et al. GDF11 ameliorated myocardial ischemia reperfusion injury by antioxidant stress and up-regulating autophagy in STZ-induced type 1 diabetic rats. Acta Cir Bras. 2020;34(11):e201901106.31939595 10.1590/s0102-865020190110000006
46. Zhao Y GDF11 enhances therapeutic efficacy of mesenchymal stem cells for myocardial infarction via YME1L-mediated OPA1 processing Stem Cells Transl Med 2020 9 10 1257 1271 10.1002/sctm.20-0005 32515551
Zhao Y, et al. GDF11 enhances therapeutic efficacy of mesenchymal stem cells for myocardial infarction via YME1L-mediated OPA1 processing. Stem Cells Transl Med. 2020;9(10):1257–71.32515551 10.1002/sctm.20-0005
47. Li Z GDF11 inhibits cardiomyocyte pyroptosis and exerts cardioprotection in acute myocardial infarction mice by upregulation of transcription factor HOXA3 Cell Death Dis 2020 11 10 917 10.1038/s41419-020-03120-6 33100331
Li Z, et al. GDF11 inhibits cardiomyocyte pyroptosis and exerts cardioprotection in acute myocardial infarction mice by upregulation of transcription factor HOXA3. Cell Death Dis. 2020;11(10):917.33100331 10.1038/s41419-020-03120-6
48. Schmidt CW Diversity outbred: a new generation of mouse model Environ Health Perspect 2015 123 3 A64 A67 10.1289/ehp.123-A64 25730842
Schmidt CW. Diversity outbred: a new generation of mouse model. Environ Health Perspect. 2015;123(3):A64–7.25730842 10.1289/ehp.123-A64
49. Churchill GA The diversity outbred mouse population Mamm Genome 2012 23 713 718 10.1007/s00335-012-9414-2 22892839
Churchill GA, et al. The diversity outbred mouse population. Mamm Genome. 2012;23:713–8.22892839 10.1007/s00335-012-9414-2
50. Gatti DM Quantitative trait locus mapping methods for diversity outbred mice G3 (Bethesda) 2014 4 9 1623 33 10.1534/g3.114.013748 25237114
Gatti DM, et al. Quantitative trait locus mapping methods for diversity outbred mice. G3 (Bethesda). 2014;4(9):1623–33.25237114 10.1534/g3.114.013748
51. Starcher AE, et al. A systems approach using Diversity Outbred mice distinguishes the cardiovascular effects and genetics of circulating GDF11 from those of its homolog, myostatin. G3 (Bethesda), 2021. 11(11).
52. Rutenberg JB Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors Development 2006 133 21 4381 4390 10.1242/dev.02607 17021042
Rutenberg JB, et al. Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors. Development. 2006;133(21):4381–90.17021042 10.1242/dev.02607
53. Fischer A Combined loss of Hey1 and HeyL causes congenital heart defects because of impaired epithelial to mesenchymal transition Circ Res 2007 100 6 856 863 10.1161/01.RES.0000260913.95642.3b 17303760
Fischer A, et al. Combined loss of Hey1 and HeyL causes congenital heart defects because of impaired epithelial to mesenchymal transition. Circ Res. 2007;100(6):856–63.17303760 10.1161/01.RES.0000260913.95642.3b
54. Fischer A The Notch target genes Hey1 and Hey2 are required for embryonic vascular development Genes Dev 2004 18 8 901 911 10.1101/gad.291004 15107403
Fischer A, et al. The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev. 2004;18(8):901–11.15107403 10.1101/gad.291004
55. Watanabe Y Importance of endothelial Hey1 expression for thoracic great vessel development and its distal enhancer for notch-dependent endothelial transcription J Biol Chem 2020 295 51 17632 17645 10.1074/jbc.RA120.015003 33454003
Watanabe Y, et al. Importance of endothelial Hey1 expression for thoracic great vessel development and its distal enhancer for notch-dependent endothelial transcription. J Biol Chem. 2020;295(51):17632–45.33454003 10.1074/jbc.RA120.015003
56. Albert FW Kruglyak L The role of regulatory variation in complex traits and disease Nat Rev Genet 2015 16 4 197 212 10.1038/nrg3891 25707927
Albert FW, Kruglyak L. The role of regulatory variation in complex traits and disease. Nat Rev Genet. 2015;16(4):197–212.25707927 10.1038/nrg3891
57. Skelly DA Ronald J Akey JM Inherited variation in gene expression Annu Rev Genomics Hum Genet 2009 10 313 332 10.1146/annurev-genom-082908-150121 19630563
Skelly DA, Ronald J, Akey JM. Inherited variation in gene expression. Annu Rev Genomics Hum Genet. 2009;10:313–32.19630563 10.1146/annurev-genom-082908-150121
58. Qu W Identification of splicing Quantitative Trait Loci (sQTL) in drosophila melanogaster with developmental lead (Pb(2+)) exposure Front Genet 2017 8 145 145 10.3389/fgene.2017.00145 29114259
Qu W, et al. Identification of splicing Quantitative Trait Loci (sQTL) in drosophila melanogaster with developmental lead (Pb(2+)) exposure. Front Genet. 2017;8:145–145.29114259 10.3389/fgene.2017.00145
59. van der Wijst M The single-cell eQTLGen consortium eLife 2020 9 e52155
van der Wijst M, et al. The single-cell eQTLGen consortium eLife. 2020;9:e52155.
60. ConsortiumG.T. The Genotype-Tissue Expression (GTEx) project Nat Genet 2013 45 6 580 585 10.1038/ng.2653 23715323
Consortium, G.T. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580–5.23715323 10.1038/ng.2653
61. Madeira F, et al. Search and sequence analysis tools services from EMBL-EBI in 2022. Nucleic Acids Res. 2022;50(W1):W276-9.
62. Blake JA Mouse Genome Database (MGD): Knowledgebase for mouse-human comparative biology Nucleic Acids Res 2021 49 D1 D981 d987 10.1093/nar/gkaa1083 33231642
Blake JA, et al. Mouse Genome Database (MGD): Knowledgebase for mouse-human comparative biology. Nucleic Acids Res. 2021;49(D1):D981-d987.33231642 10.1093/nar/gkaa1083
63. Baldarelli RM The mouse Gene Expression Database (GXD): 2021 update Nucleic Acids Res 2021 49 D1 D924 D931 10.1093/nar/gkaa914 33104772
Baldarelli RM, et al. The mouse Gene Expression Database (GXD): 2021 update. Nucleic Acids Res. 2021;49(D1):D924–31.33104772 10.1093/nar/gkaa914
64. Robinson JR Genome-wide and phenome-wide approaches to understand variable drug actions in electronic health records Clin Transl Sci 2018 11 2 112 122 10.1111/cts.12522 29148204
Robinson JR, et al. Genome-wide and phenome-wide approaches to understand variable drug actions in electronic health records. Clin Transl Sci. 2018;11(2):112–22.29148204 10.1111/cts.12522
65. Stearns FW One hundred years of pleiotropy: a retrospective Genetics 2010 186 3 767 773 10.1534/genetics.110.122549 21062962
Stearns FW. One hundred years of pleiotropy: a retrospective. Genetics. 2010;186(3):767–73.21062962 10.1534/genetics.110.122549
66. Diogo D Phenome-wide association studies across large population cohorts support drug target validation Nat Commun 2018 9 1 4285 10.1038/s41467-018-06540-3 30327483
Diogo D, et al. Phenome-wide association studies across large population cohorts support drug target validation. Nat Commun. 2018;9(1):4285.30327483 10.1038/s41467-018-06540-3
67. Gusev A Integrative approaches for large-scale transcriptome-wide association studies Nat Genet 2016 48 3 245 252 10.1038/ng.3506 26854917
Gusev A, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016;48(3):245–52.26854917 10.1038/ng.3506
68. Bhattacharya A A framework for transcriptome-wide association studies in breast cancer in diverse study populations Genome Biol 2020 21 1 42 10.1186/s13059-020-1942-6 32079541
Bhattacharya A, et al. A framework for transcriptome-wide association studies in breast cancer in diverse study populations. Genome Biol. 2020;21(1):42.32079541 10.1186/s13059-020-1942-6
69. Gamazon ER A gene-based association method for mapping traits using reference transcriptome data Nat Genet 2015 47 9 1091 1098 10.1038/ng.3367 26258848
Gamazon ER, et al. A gene-based association method for mapping traits using reference transcriptome data. Nat Genet. 2015;47(9):1091–8.26258848 10.1038/ng.3367
70. Mancuso N Integrating gene expression with summary association statistics to identify genes associated with 30 complex traits Am J Hum Genet 2017 100 3 473 487 10.1016/j.ajhg.2017.01.031 28238358
Mancuso N, et al. Integrating gene expression with summary association statistics to identify genes associated with 30 complex traits. Am J Hum Genet. 2017;100(3):473–87.28238358 10.1016/j.ajhg.2017.01.031
71. Bycroft C The UK Biobank resource with deep phenotyping and genomic data Nature 2018 562 7726 203 209 10.1038/s41586-018-0579-z 30305743
Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203–9.30305743 10.1038/s41586-018-0579-z
72. Carithers LJ A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project Biopreservation and biobanking 2015 13 5 311 319 10.1089/bio.2015.0032 26484571
Carithers LJ, et al. A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project. Biopreservation and biobanking. 2015;13(5):311–9.26484571 10.1089/bio.2015.0032
73. Siminoff LA Consent to a Postmortem tissue procurement study: distinguishing family decision makers’ knowledge of the genotype-tissue expression project Biopreserv Biobank 2018 16 3 200 206 10.1089/bio.2017.0115 29746160
Siminoff LA, et al. Consent to a Postmortem tissue procurement study: distinguishing family decision makers’ knowledge of the genotype-tissue expression project. Biopreserv Biobank. 2018;16(3):200–6.29746160 10.1089/bio.2017.0115
74. ConsortiumG.T., Genetic effects on gene expression across human tissues Nature 2017 550 7675 204 213 10.1038/nature24277 29022597
Consortium, G.T., et al. Genetic effects on gene expression across human tissues. Nature. 2017;550(7675):204–13.29022597 10.1038/nature24277
75. The Genotype-Tissue Expression (GTEx) Project; Available from: https://www.gtexportal.org/home/. Cited 2022 Nov 8.
76. Wright FA Heritability and genomics of gene expression in peripheral blood Nat Genet 2014 46 5 430 437 10.1038/ng.2951 24728292
Wright FA, et al. Heritability and genomics of gene expression in peripheral blood. Nat Genet. 2014;46(5):430–7.24728292 10.1038/ng.2951
77. TWAS Hub. Available from: http://twas-hub.org/. Cited 2022 Nov 8.
78. Fromer M Gene expression elucidates functional impact of polygenic risk for schizophrenia Nat Neurosci 2016 19 11 1442 1453 10.1038/nn.4399 27668389
Fromer M, et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci. 2016;19(11):1442–53.27668389 10.1038/nn.4399
79. Stancáková A Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men Diabetes 2012 61 7 1895 1902 10.2337/db11-1378 22553379
Stancáková A, et al. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish men. Diabetes. 2012;61(7):1895–902.22553379 10.2337/db11-1378
80. Stancáková A Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men Diabetes 2009 58 5 1212 1221 10.2337/db08-1607 19223598
Stancáková A, et al. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes. 2009;58(5):1212–21.19223598 10.2337/db08-1607
81. Raitakari OT Cohort profile: the cardiovascular risk in Young Finns Study Int J Epidemiol 2008 37 6 1220 1226 10.1093/ije/dym225 18263651
Raitakari OT, et al. Cohort profile: the cardiovascular risk in Young Finns Study. Int J Epidemiol. 2008;37(6):1220–6.18263651 10.1093/ije/dym225
82. Nuotio J Cardiovascular risk factors in 2011 and secular trends since 2007: the Cardiovascular Risk in Young Finns Study Scand J Public Health 2014 42 7 563 571 10.1177/1403494814541597 25053467
Nuotio J, et al. Cardiovascular risk factors in 2011 and secular trends since 2007: the Cardiovascular Risk in Young Finns Study. Scand J Public Health. 2014;42(7):563–71.25053467 10.1177/1403494814541597
83. Pividori M, et al. PhenomeXcan: Mapping the genome to the phenome through the transcriptome. BioRxiv. 2020;6(37):eaba2083.
84. Barbeira AN, et al. Exploiting the GTEx resources to decipher the mechanisms at GWAS loci. Genome Biol. 2021;22(1):49.
85. PhenomeXcan. Available from: http://apps.hakyimlab.org/phenomexcan/. Cited 2022 Nov 8.
86. Ghoussaini M Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics Nucleic Acids Res 2021 49 D1 D1311 D1320 10.1093/nar/gkaa840 33045747
Ghoussaini M, et al. Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics. Nucleic Acids Res. 2021;49(D1):D1311–20.33045747 10.1093/nar/gkaa840
87. Mountjoy E An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci Nat Genet 2021 53 11 1527 1533 10.1038/s41588-021-00945-5 34711957
Mountjoy E, et al. An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci. Nat Genet. 2021;53(11):1527–33.34711957 10.1038/s41588-021-00945-5
88. Open Targets Genetics. Available from: https://genetics.opentargets.org/. Cited 2022 Nov 8.
89. Buniello A The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 Nucleic Acids Res 2019 47 D1 D1005 d1012 10.1093/nar/gky1120 30445434
Buniello A, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47(D1):D1005-d1012.30445434 10.1093/nar/gky1120
90. Zhou W Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies Nat Genet 2018 50 9 1335 1341 10.1038/s41588-018-0184-y 30104761
Zhou W, et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet. 2018;50(9):1335–41.30104761 10.1038/s41588-018-0184-y
91. Lab N UK Biobank bulk summary statistics 2018
Lab N. UK Biobank bulk summary statistics. 2018.
92. Võsa U, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53(9):1300-10.
93. Sun BB Genomic atlas of the human plasma proteome Nature 2018 558 7708 73 79 10.1038/s41586-018-0175-2 29875488
Sun BB, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558(7708):73–9.29875488 10.1038/s41586-018-0175-2
94. Kamat MA PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations Bioinformatics 2019 35 22 4851 4853 10.1093/bioinformatics/btz469 31233103
Kamat MA, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019;35(22):4851–3.31233103 10.1093/bioinformatics/btz469
95. Staley JR PhenoScanner: a database of human genotype-phenotype associations Bioinformatics 2016 32 20 3207 3209 10.1093/bioinformatics/btw373 27318201
Staley JR, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics. 2016;32(20):3207–9.27318201 10.1093/bioinformatics/btw373
96. PhenoScanner. Available from: http://www.phenoscanner.medschl.cam.ac.uk/. Cited 2022 Nov 8.
97. Canela-Xandri O Rawlik K Tenesa A An atlas of genetic associations in UK Biobank Nat Genet 2018 50 11 1593 1599 10.1038/s41588-018-0248-z 30349118
Canela-Xandri O, Rawlik K, Tenesa A. An atlas of genetic associations in UK Biobank. Nat Genet. 2018;50(11):1593–9.30349118 10.1038/s41588-018-0248-z
98. Gene ATLAS. Available from: http://geneatlas.roslin.ed.ac.uk/. Cited 2022 Nov 8.
99. Yang S Ye K Recent advances in understanding the adaptive evolution of metabolic genes and traits Curr Opin Clin Nutr Metab Care 2021 24 4 308 314 10.1097/MCO.0000000000000770 34039840
Yang S, Ye K. Recent advances in understanding the adaptive evolution of metabolic genes and traits. Curr Opin Clin Nutr Metab Care. 2021;24(4):308–14.34039840 10.1097/MCO.0000000000000770
100. Du G-Q Targeted myocardial delivery of GDF11 gene rejuvenates the aged mouse heart and enhances myocardial regeneration after ischemia–reperfusion injury Basic Res Cardiol 2017 112 1 14 10.1007/s00395-016-0593-y 27837311
Du G-Q, et al. Targeted myocardial delivery of GDF11 gene rejuvenates the aged mouse heart and enhances myocardial regeneration after ischemia–reperfusion injury. Basic Res Cardiol. 2017;112:1–14.27837311 10.1007/s00395-016-0593-y
101. Holgate ST Asthma: a simple concept but in reality a complex disease Eur J Clin Invest 2011 41 12 1339 1352 10.1111/j.1365-2362.2011.02534.x 21615731
Holgate ST. Asthma: a simple concept but in reality a complex disease. Eur J Clin Invest. 2011;41(12):1339–52.21615731 10.1111/j.1365-2362.2011.02534.x
102. Win PH, Hussain I. Asthma Triggers: What Really Matters? Clinical Asthma. 2008:149-56.
103. Frossing L The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma J Allergy Clin Immunol Pract 2021 9 3 1267 1275 10.1016/j.jaip.2020.09.051 33039645
Frossing L, et al. The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma. J Allergy Clin Immunol Pract. 2021;9(3):1267–75.33039645 10.1016/j.jaip.2020.09.051
104. Vos T, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–22.
105. Mims JW Asthma: definitions and pathophysiology Int Forum Allergy Rhinol 2015 5 Suppl 1 S2 6 26335832
Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S2-6.26335832
106. Bunyavanich S Schadt EE Systems biology of asthma and allergic diseases: a multiscale approach J Allergy Clin Immunol 2015 135 1 31 42 10.1016/j.jaci.2014.10.015 25468194
Bunyavanich S, Schadt EE. Systems biology of asthma and allergic diseases: a multiscale approach. J Allergy Clin Immunol. 2015;135(1):31–42.25468194 10.1016/j.jaci.2014.10.015
107. Fahy JV Type 2 inflammation in asthma - present in most, absent in many Nat Rev Immunol 2015 15 57 65 10.1038/nri3786 25534623
Fahy JV. Type 2 inflammation in asthma - present in most, absent in many. Nat Rev Immunol. 2015;15:57–65.25534623 10.1038/nri3786
108. Kuruvilla ME Lee FE Lee GB Understanding asthma phenotypes, endotypes, and mechanisms of disease Clin Rev Allergy Immunol 2019 56 2 219 233 10.1007/s12016-018-8712-1 30206782
Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–33.30206782 10.1007/s12016-018-8712-1
109. Denlinger LC Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations Am J Respir Crit Care Med 2017 195 3 302 313 10.1164/rccm.201602-0419OC 27556234
Denlinger LC, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195(3):302–13.27556234 10.1164/rccm.201602-0419OC
110. Price DB Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study Lancet Respir Med 2015 3 11 849 858 10.1016/S2213-2600(15)00367-7 26493938
Price DB, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–58.26493938 10.1016/S2213-2600(15)00367-7
111. Green RH Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial The Lancet 2002 360 9347 1715 1721 10.1016/S0140-6736(02)11679-5
Green RH, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. The Lancet. 2002;360(9347):1715–21.10.1016/S0140-6736(02)11679-5
112. Loffredo FS Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy Cell 2013 153 4 828 839 10.1016/j.cell.2013.04.015 23663781
Loffredo FS, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153(4):828–39.23663781 10.1016/j.cell.2013.04.015
113. McPherron AC Metabolic functions of myostatin and GDF11 Immunology Endocr Metab AgentsMed Chem (Formerly Current Medicinal Chemistry-Immunology Endocrine and Metabolic Agents) 2010 10 4 217 231 10.2174/187152210793663810
McPherron AC. Metabolic functions of myostatin and GDF11. Immunology Endocr Metab AgentsMed Chem (Formerly Current Medicinal Chemistry-Immunology Endocrine and Metabolic Agents). 2010;10(4):217–31.10.2174/187152210793663810
114. Bronte V Pittet MJ The spleen in local and systemic regulation of immunity Immunity 2013 39 5 806 818 10.1016/j.immuni.2013.10.010 24238338
Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity. 2013;39(5):806–18.24238338 10.1016/j.immuni.2013.10.010
115. Travers J Rothenberg M Eosinophils in mucosal immune responses Mucosal Immunol 2015 8 3 464 475 10.1038/mi.2015.2 25807184
Travers J, Rothenberg M. Eosinophils in mucosal immune responses. Mucosal Immunol. 2015;8(3):464–75.25807184 10.1038/mi.2015.2
116. Lewis, S.M., A. Williams, and S.C. Eisenbarth, Structure and function of the immune system in the spleen. Sci Immunol, 2019. 4(33).
117. Chaker L Hypothyroidism The Lancet 2017 390 10101 1550 1562 10.1016/S0140-6736(17)30703-1
Chaker L, et al. Hypothyroidism. The Lancet. 2017;390(10101):1550–62.10.1016/S0140-6736(17)30703-1
118. Chiovato L Magri F Carlé A Hypothyroidism in context: where we’ve been and where we’re going Adv Ther 2019 36 Suppl 2 47 58 10.1007/s12325-019-01080-8 31485975
Chiovato L, Magri F, Carlé A. Hypothyroidism in context: where we’ve been and where we’re going. Adv Ther. 2019;36(Suppl 2):47–58.31485975 10.1007/s12325-019-01080-8
119. Taylor PN Global epidemiology of hyperthyroidism and hypothyroidism Nat Rev Endocrinol 2018 14 5 301 316 10.1038/nrendo.2018.18 29569622
Taylor PN, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301–16.29569622 10.1038/nrendo.2018.18
120. Persani L Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges J Clin Endocrinol Metab 2012 97 9 3068 3078 10.1210/jc.2012-1616 22851492
Persani L. Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab. 2012;97(9):3068–78.22851492 10.1210/jc.2012-1616
121. Porcu E A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function PLoS Genet 2013 9 2 e1003266 10.1371/journal.pgen.1003266 23408906
Porcu E, et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet. 2013;9(2):e1003266.23408906 10.1371/journal.pgen.1003266
122. Teumer A Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation Nat Commun 2018 9 1 4455 10.1038/s41467-018-06356-1 30367059
Teumer A, et al. Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation. Nat Commun. 2018;9(1):4455.30367059 10.1038/s41467-018-06356-1
123. Taylor PN Whole-genome sequence-based analysis of thyroid function Nat Commun 2015 6 5681 10.1038/ncomms6681 25743335
Taylor PN, et al. Whole-genome sequence-based analysis of thyroid function. Nat Commun. 2015;6:5681.25743335 10.1038/ncomms6681
124. Añón-Hidalgo J Circulating concentrations of GDF11 are positively associated with TSH levels in humans J Clin Med 2019 8 6 878 10.3390/jcm8060878 31248139
Añón-Hidalgo J, et al. Circulating concentrations of GDF11 are positively associated with TSH levels in humans. J Clin Med. 2019;8(6):878.31248139 10.3390/jcm8060878
125. Li W GDF11 antagonizes TNF-α-induced inflammation and protects against the development of inflammatory arthritis in mice Faseb j 2019 33 3 3317 3329 10.1096/fj.201801375RR 30407878
Li W, et al. GDF11 antagonizes TNF-α-induced inflammation and protects against the development of inflammatory arthritis in mice. Faseb j. 2019;33(3):3317–29.30407878 10.1096/fj.201801375RR
126. Mei W GDF11 protects against endothelial injury and reduces atherosclerotic lesion formation in apolipoprotein E-null mice Mol Ther 2016 24 11 1926 1938 10.1038/mt.2016.160 27502608
Mei W, et al. GDF11 protects against endothelial injury and reduces atherosclerotic lesion formation in apolipoprotein E-null mice. Mol Ther. 2016;24(11):1926–38.27502608 10.1038/mt.2016.160
127. Xu HB Growth differentiation factor 11 relieves acute lung injury in mice by inhibiting inflammation and apoptosis Eur Rev Med Pharmacol Sci 2020 24 12 6908 6918 32633384
Xu HB, et al. Growth differentiation factor 11 relieves acute lung injury in mice by inhibiting inflammation and apoptosis. Eur Rev Med Pharmacol Sci. 2020;24(12):6908–18.32633384
128. Onodera K Decrease in an anti-ageing factor, growth differentiation factor 11, in chronic obstructive pulmonary disease Thorax 2017 72 10 893 904 10.1136/thoraxjnl-2016-209352 28455454
Onodera K, et al. Decrease in an anti-ageing factor, growth differentiation factor 11, in chronic obstructive pulmonary disease. Thorax. 2017;72(10):893–904.28455454 10.1136/thoraxjnl-2016-209352
129. Tanaka R Physical inactivity is associated with decreased growth differentiation factor 11 in chronic obstructive pulmonary disease Int J Chron Obstruct Pulmon Dis 2018 13 1333 1342 10.2147/COPD.S157035 29731621
Tanaka R, et al. Physical inactivity is associated with decreased growth differentiation factor 11 in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:1333–42.29731621 10.2147/COPD.S157035
130. Tang F Ling C Liu J Reduced expression of growth differentiation factor 11 promoted the progression of chronic obstructive pulmonary disease by activating the AKT signaling pathway Biomed Pharmacother 2018 103 691 698 10.1016/j.biopha.2018.04.091 29680737
Tang F, Ling C, Liu J. Reduced expression of growth differentiation factor 11 promoted the progression of chronic obstructive pulmonary disease by activating the AKT signaling pathway. Biomed Pharmacother. 2018;103:691–8.29680737 10.1016/j.biopha.2018.04.091
131. Ishmael FT The inflammatory response in the pathogenesis of asthma J Am Osteopath Assoc 2011 111 11 Suppl 7 S11 S17 22162373
Ishmael FT. The inflammatory response in the pathogenesis of asthma. J Am Osteopath Assoc. 2011;111(11 Suppl 7):S11–7.22162373
132. Murdoch JR Lloyd CM Chronic inflammation and asthma Mutat Res 2010 690 1–2 24 39 10.1016/j.mrfmmm.2009.09.005 19769993
Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res. 2010;690(1–2):24–39.19769993 10.1016/j.mrfmmm.2009.09.005
133. Mancini A Thyroid hormones, oxidative stress, and inflammation Mediators Inflamm 2016 2016 6757154 6757154 10.1155/2016/6757154 27051079
Mancini A, et al. Thyroid hormones, oxidative stress, and inflammation. Mediators Inflamm. 2016;2016:6757154–6757154.27051079 10.1155/2016/6757154
134. Tedeschi A Asero R Asthma and autoimmunity: a complex but intriguing relation Expert Rev Clin Immunol 2008 4 6 767 776 10.1586/1744666X.4.6.767 20477126
Tedeschi A, Asero R. Asthma and autoimmunity: a complex but intriguing relation. Expert Rev Clin Immunol. 2008;4(6):767–76.20477126 10.1586/1744666X.4.6.767
135. Manzolli S Allergic airway inflammation in hypothyroid rats J Allergy Clin Immunol 1999 104 3 Pt 1 595 600 10.1016/S0091-6749(99)70329-5 10482833
Manzolli S, et al. Allergic airway inflammation in hypothyroid rats. J Allergy Clin Immunol. 1999;104(3 Pt 1):595–600.10482833 10.1016/S0091-6749(99)70329-5
136. Sato A A possible role of immunoglobulin E in patients with hyperthyroid graves' disease J Clin Endocrinol Metab 1999 84 10 3602 3605 10523002
Sato A, et al. A possible role of immunoglobulin E in patients with hyperthyroid graves’ disease. J Clin Endocrinol Metab. 1999;84(10):3602–5.10523002
137. Goldacre M Use of large medical databases to study associations between diseases QJM 2000 93 10 669 675 10.1093/qjmed/93.10.669 11029477
Goldacre M, et al. Use of large medical databases to study associations between diseases. QJM. 2000;93(10):669–75.11029477 10.1093/qjmed/93.10.669
138. Hoffman DA McConahey WM Thyrotoxicosis and asthma Lancet 1982 1 8275 808 10.1016/S0140-6736(82)91861-X 6121259
Hoffman DA, McConahey WM. Thyrotoxicosis and asthma. Lancet. 1982;1(8275):808.6121259 10.1016/S0140-6736(82)91861-X
139. Ursu HI Graves'-Basedow's disease–asthma association. Presentation of five cases Rom J Endocrinol 1993 31 1–2 89 94 8173579
Ursu HI, et al. Graves’-Basedow’s disease–asthma association. Presentation of five cases. Rom J Endocrinol. 1993;31(1–2):89–94.8173579
140. Bingyan Z Dong W Impact of thyroid hormones on asthma in older adults J Int Med Res 2019 47 9 4114 4125 10.1177/0300060519856465 31280621
Bingyan Z, Dong W. Impact of thyroid hormones on asthma in older adults. J Int Med Res. 2019;47(9):4114–25.31280621 10.1177/0300060519856465
141. Qashqary M Prevalence of suspected cases of hyperthyroidism in Jeddah by using wayne’s scoring index Cureus 2020 12 11 e11538 e11538 33354482
Qashqary M, et al. Prevalence of suspected cases of hyperthyroidism in Jeddah by using wayne’s scoring index. Cureus. 2020;12(11):e11538–e11538.33354482
142. Oppedal RJ Khan DA Brown ES Hypothyroidism in patients with asthma and major depressive disorder Primary care companion to the Journal of clinical psychiatry 2007 9 6 467 468 10.4088/PCC.v09n0611d 18185831
Oppedal RJ, Khan DA, Brown ES. Hypothyroidism in patients with asthma and major depressive disorder. Primary care companion to the Journal of clinical psychiatry. 2007;9(6):467–8.18185831 10.4088/PCC.v09n0611d
143. Thorsteinsson BA Kirkegaard C Iodine-induced hypothyroidism and bronchial asthma Lancet 1979 310 8032 294 10.1016/S0140-6736(77)90972-2
Thorsteinsson BA, Kirkegaard C. Iodine-induced hypothyroidism and bronchial asthma. Lancet. 1979;310(8032):294.10.1016/S0140-6736(77)90972-2
144. Liu X Maternal hypothyroidism in the perinatal period and childhood asthma in the offspring Allergy 2018 73 4 932 939 10.1111/all.13365 29159833
Liu X, et al. Maternal hypothyroidism in the perinatal period and childhood asthma in the offspring. Allergy. 2018;73(4):932–9.29159833 10.1111/all.13365
145. Harrison RN Tattersfield AE Airway response to inhaled salbutamol in hyperthyroid and hypothyroid patients before and after treatment Thorax 1984 39 34 39 10.1136/thx.39.1.34 6695351
Harrison RN, Tattersfield AE. Airway response to inhaled salbutamol in hyperthyroid and hypothyroid patients before and after treatment. Thorax. 1984;39:34–9.6695351 10.1136/thx.39.1.34
146. Fedrick J Baldwin JA Thyroid disease and asthma Br Med J 1977 2 6101 1539 10.1136/bmj.2.6101.1539-a 589324
Fedrick J, Baldwin JA. Thyroid disease and asthma. Br Med J. 1977;2(6101):1539.589324 10.1136/bmj.2.6101.1539-a
147. Weare-Regales N Hormonal effects on asthma, rhinitis, and eczema J Allergy Clin Immunol Pract 2022 10 8 2066 2073 10.1016/j.jaip.2022.04.002 35436605
Weare-Regales N, et al. Hormonal effects on asthma, rhinitis, and eczema. J Allergy Clin Immunol Pract. 2022;10(8):2066–73.35436605 10.1016/j.jaip.2022.04.002
148. ConsortiumT.U. UniProt: the Universal Protein Knowledgebase in 2023 Nucleic Acids Res 2022 51 D1 D523 D531 10.1093/nar/gkac1052
Consortium, T.U. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 2022;51(D1):D523–31.10.1093/nar/gkac1052
149. Gokhale AS Selective deletion of Eos (Ikzf4) in T-regulatory cells leads to loss of suppressive function and development of systemic autoimmunity J Autoimmun 2019 105 102300 10.1016/j.jaut.2019.06.011 31296356
Gokhale AS, et al. Selective deletion of Eos (Ikzf4) in T-regulatory cells leads to loss of suppressive function and development of systemic autoimmunity. J Autoimmun. 2019;105:102300.31296356 10.1016/j.jaut.2019.06.011
150. Stéphan P, et al. Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting? Cancers (Basel). 2020;12(11):3194.
151. Weber D Mechanisms of epigenetic and cell-type specific regulation of Hey target genes in ES cells and cardiomyocytes J Mol Cell Cardiol 2015 79 79 88 10.1016/j.yjmcc.2014.11.004 25446183
Weber D, et al. Mechanisms of epigenetic and cell-type specific regulation of Hey target genes in ES cells and cardiomyocytes. J Mol Cell Cardiol. 2015;79:79–88.25446183 10.1016/j.yjmcc.2014.11.004
152. Gene Expression Database (GXD). Available from: http://www.informatics.jax.org. Cited 2022 Aug 22
153. Lee S-J McPherron AC Myostatin and the control of skeletal muscle mass: commentary Curr Opin Genet Dev 1999 9 5 604 607 10.1016/S0959-437X(99)00004-0 10508689
Lee S-J, McPherron AC. Myostatin and the control of skeletal muscle mass: commentary. Curr Opin Genet Dev. 1999;9(5):604–7.10508689 10.1016/S0959-437X(99)00004-0
154. Biesemann N Myostatin regulates energy homeostasis in the heart and prevents heart failure Circ Res 2014 115 2 296 310 10.1161/CIRCRESAHA.115.304185 24807786
Biesemann N, et al. Myostatin regulates energy homeostasis in the heart and prevents heart failure. Circ Res. 2014;115(2):296–310.24807786 10.1161/CIRCRESAHA.115.304185
155. McKoy G Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation Cardiovasc Res 2007 74 2 304 312 10.1016/j.cardiores.2007.02.023 17368590
McKoy G, et al. Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation. Cardiovasc Res. 2007;74(2):304–12.17368590 10.1016/j.cardiores.2007.02.023
156. Morissette MR Myostatin regulates cardiomyocyte growth through modulation of Akt signaling Circ Res 2006 99 1 15 24 10.1161/01.RES.0000231290.45676.d4 16763166
Morissette MR, et al. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res. 2006;99(1):15–24.16763166 10.1161/01.RES.0000231290.45676.d4
157. Hebbring SJ The challenges, advantages and future of phenome-wide association studies Immunology 2014 141 2 157 165 10.1111/imm.12195 24147732
Hebbring SJ. The challenges, advantages and future of phenome-wide association studies. Immunology. 2014;141(2):157–65.24147732 10.1111/imm.12195
